



14.03.2024

**08:15 - 08:30**    **Type: Special session**    **Hall A**  
**Title: Welcome to the ESMO Sarcoma and Rare Cancers Congress 2024**

08:15 - 08:35    **Welcome to the ESMO Sarcoma and Rare Cancers Congress 2024**

**08:30 - 10:00**    **Type: Educational session**    **Hall A**  
**Title: MDM2**  
Moderation: William D. Tap, United States of America; Sarah Watson, France

08:30 - 08:50    **MDM2 copy number**  
Sarah Watson, Institut Curie, Paris, France

08:50 - 09:10    **Potential combination therapies**  
William D. Tap, MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

09:10 - 09:30    **Non-P53 roles of MDM2**  
Laetitia Linares, Institut de recherche en cancérologie de Montpellier, montpellier, France

09:30 - 09:50    **Other MDM2 amplified sarcomas: The value of MDM2 inhibitors**  
Hans Gelderblom, LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands

09:50 - 10:00    **Q&A and discussion**



**08:30 - 10:00**    **Type: Educational session**    **Hall B1**  
**Title: Genitourinary cancers**  
Moderation: Jourik Gietema, Netherlands; Alejo Rodriguez-Vida, Spain

08:30 - 08:50    **Small cell tumours of the bladder**  
Alejo Rodriguez-Vida, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain

08:50 - 09:10    **Difficult-to-treat testicular germ cell tumours**  
Jourik Gietema, UMCG - University Medical Center Groningen, Groningen, Netherlands

09:10 - 09:30    **Collecting duct carcinoma of the kidney**  
Constance Thibault, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France

09:30 - 09:50    **Neuro-endocrine tumours of the prostate**  
Pasquale Rescigno, Newcastle University, Newcastle upon Tyne, United Kingdom

09:50 - 10:00    **Q&A and discussion**

**08:30 - 10:00**    **Type: Educational session**    **Hall B3**  
**Title: Methodology**  
Moderation: Annalisa Trama, Italy; Denis Lacombe, Belgium

08:30 - 08:50    **Pragmatic clinical trials in rare cancers**  
Denis Lacombe, EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium

08:50 - 09:10    **Drug repurposing experience in rare cancers**  
Pan Pantziarka, Anticancer Fund, Strombeek-Bever, Belgium

09:10 - 09:30    **Observational studies, old and new approaches**  
Annalisa Trama, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

09:30 - 09:50    **Big data and AI for rare cancers**  
Gijs Geleijnse, IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands

09:50 - 10:00    **Q&A and discussion**

**10:00 - 10:30**    **Type: Coffee break**    **Foyer Ground Floor**  
**Title: Coffee break**



**10:30 - 12:00** **Type: Educational session** **Hall A**  
**Title: TGCT**  
Moderation: Michiel van de Sande, Netherlands; Beatrice Seddon, United Kingdom

10:30 - 10:50 **What should be considered standard surgery?**  
Michiel Van De Sande, Leiden University Medical Center, Leiden, Netherlands

10:50 - 11:10 **What is the optimal duration of systemic therapy?**  
Armelle Dufresne, Centre Léon Bérard, Lyon, CEDEX 3, France

11:10 - 11:30 **Does radiation play a part in the management of TGCT?**  
Beatrice Seddon, UCLH - University College London Hospitals NHS Foundation Trust, London, United Kingdom

11:30 - 11:50 **Biological understanding of the disease**  
Torsten Nielsen, Vancouver General Hospital & HSC, British Columbia University, Vancouver, British Columbia, Canada

11:50 - 12:00 **Q&A and discussion**

**10:30 - 12:00** **Type: Abstract session** **Hall B1**  
**Title: Proffered Paper session 1**  
Moderation: Robin Jones, United Kingdom; Silvia Stacchiotti, Italy

10:30 - 10:40 **390 - Four years and 1400 patient referrals: Achievements of the Australian Rare Cancer Portal**  
Betty Zhang<sup>1</sup>; C. Georgiou<sup>2</sup>; C. Turner<sup>3</sup>; D. Kee<sup>4</sup>; D. Goldstein<sup>4</sup>; J. Haurat<sup>5</sup>; A. Bourne<sup>5</sup>; M. Turner<sup>5</sup>; C. Scott<sup>6</sup>, <sup>1</sup>Australian Rare Cancer Portal, Parkville, VIC, Australia, <sup>2</sup>Australia Rare Cancer Portal, Melbourne, VIC, Australia, <sup>3</sup>Australian Rare Cancer Portal, Melbourne, VIC, Australia, <sup>4</sup>Australian Rare Cancer Portal, Melbourne, Australia, <sup>5</sup>BioGrid, Melbourne, Australia, <sup>6</sup>Australian Rare Cancer Portal, Parkville, Australia

10:40 - 10:50 **Invited Discussant abstract 390**  
Amanda Psyrri, Attikon University Hospital, Haidari, Greece

10:50 - 11:00 **Q&A and discussion**

11:00 - 11:10 **520 - Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study**  
J.-Y. Blay<sup>1</sup>; Quentin Devin<sup>2</sup>; F. Duffaud<sup>3</sup>; M. Toulmonde<sup>4</sup>; N. Firmin<sup>5</sup>; O. Collard<sup>6</sup>; E. Bompas<sup>7</sup>; B. Verret<sup>8</sup>; I. Ray-Coquard<sup>9</sup>; S. Salas<sup>10</sup>; C. Henon<sup>11</sup>; C. Honoré<sup>12</sup>; M. Brahmi<sup>9</sup>; A. Dufresne<sup>13</sup>; M. Pracht<sup>14</sup>; N. Penel<sup>15</sup>; D. Perol<sup>9</sup>; S. Chabaud<sup>16</sup>; A. Italiano<sup>4</sup>; A. Le Cesne<sup>17</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, France, <sup>2</sup>Entre Leon Berard & Faculté Lyon Est



UCBL Lyon<sup>1</sup>, Lyon, France, <sup>3</sup>CHU La Timone Adultes, Marseille, CEDEX 5, France, <sup>4</sup>Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, CEDEX, France, <sup>5</sup>Icm Val D Aurelle, Montpellier, France, <sup>6</sup>Hopital Privé de la Loire, Saint Etienne, France, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, CEDEX, France, <sup>8</sup>Institut Gustave Roussy, Villejuif, France, <sup>9</sup>Centre Léon Bérard, Lyon, CEDEX, France, <sup>10</sup>AP-HM - CHU La Timone Enfants, Marseille, France, <sup>11</sup>Institut Gustave Roussy, Villejuif, Cedex, France, <sup>12</sup>Gustave Roussy - Cancer Campus, Villejuif, France, <sup>13</sup>Centre Léon Bérard, Lyon, CEDEX 3, France, <sup>14</sup>Centre Eugene - Marquis, Rennes, CEDEX, France, <sup>15</sup>Centre Oscar Lambret, Lille, CEDEX, France, <sup>16</sup>Centre de recherche en cancerologie de Lyon (CRCL), Lyon, France, <sup>17</sup>Gustave Roussy - Cancer Campus, Villejuif, CEDEX, France

11:10 - 11:20

**530 - Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma**

Seth Pollack<sup>1</sup>; A. Conley<sup>2</sup>; W.D. Tap<sup>3</sup>; C.-C. Yen<sup>4</sup>; J. Charlson<sup>5</sup>; L. Davis<sup>6</sup>; A. Chalmers<sup>7</sup>; M. Druta<sup>8</sup>; E. Loggers<sup>9</sup>; J. Grewal<sup>10</sup>; G. Falchook<sup>11</sup>; B. Schulte<sup>12</sup>; T. Yau<sup>13</sup>; A. Kim<sup>14</sup>; H.H.F. Loong<sup>15</sup>; S. George<sup>16</sup>; B. Setty<sup>17</sup>; L. Mascarenhas<sup>18</sup>; G. Cote<sup>19</sup>; B. Wilky<sup>20</sup>,

<sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America, <sup>2</sup>MD Anderson Cancer Center, Houston, TX, United States of America, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America, <sup>4</sup>School of Medicine, College of Medicine and Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei City, Taiwan, <sup>5</sup>Froedtert Hospital & Medical College of Wisconsin, Milwaukee, United States of America, <sup>6</sup>Oregon Health & Science University, Portland, OR, United States of America, <sup>7</sup>Huntsman Cancer Institute, Salt Lake City, UT, United States of America, <sup>8</sup>Moffitt Cancer Center, Tampa, FL, United States of America, <sup>9</sup>Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, United States of America, <sup>10</sup>Norton Cancer Institute, Louisville, KY, United States of America, <sup>11</sup>Sarah Cannon Research Institute at HealthONE, Denver, CO, United States of America, <sup>12</sup>University of California, San Francisco, San Francisco, CA, United States of America, <sup>13</sup>University of Hong Kong, Hong Kong, Pokfulam, Hong Kong PRC, <sup>14</sup>Children's National Hospital, Washington, DC, United States of America, <sup>15</sup>The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong PRC, <sup>16</sup>Dana-Farber Cancer Institute, Boston, MA, United States of America, <sup>17</sup>Nationwide Children's Hospital, The Ohio State University, Columbus, OH, United States of America, <sup>18</sup>Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America, <sup>19</sup>Mass General Cancer Center, Boston, MA, United States of America, <sup>20</sup>University of Colorado, Aurora, CO, United States of America

11:20 - 11:30

**540 - Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1**

Michael Wagner<sup>1</sup>; C. Lunt<sup>2</sup>; D. Araujo<sup>3</sup>; J.-Y. Blay<sup>4</sup>; M. Druta<sup>5</sup>; S. Attia<sup>6</sup>; C.M. Valverde Morales<sup>7</sup>; K. Ganjoo<sup>8</sup>; S. Schuetze<sup>9</sup>; E. Van Winkle<sup>10</sup>; P. Bayer<sup>10</sup>; J. Bai<sup>10</sup>; D. Bestul<sup>10</sup>; V. Desai<sup>10</sup>; M. Yule<sup>2</sup>; D. Williams<sup>10</sup>; E. Norry<sup>10</sup>; B. Van Tine<sup>11</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, United States of America, <sup>2</sup>Adaptimmune, Abingdon-on-Thames, United Kingdom, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, United States of America, <sup>4</sup>Centre Léon Bérard, Lyon, CEDEX, France, <sup>5</sup>Moffitt Cancer Center, Tampa, United States of America, <sup>6</sup>Mayo Clinic - Florida, Jacksonville, United States of America, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>8</sup>Stanford University Medical



Center, Stanford, CA, United States of America, <sup>9</sup>University Hospital - Michigan Medicine, Ann Arbor, MI, United States of America, <sup>10</sup>Adaptimmune, Philadelphia, United States of America, <sup>11</sup>Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States of America

11:30 - 11:45 **Invited Discussant abstracts 520, 530 and 540**

Hanna Kosela Paterczyk, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

11:45 - 12:00 **Q&A and discussion**

**10:30 - 12:00 Type: Educational session  
Title: Digestive cancers**

**Hall B3**

Moderation: Dirk Arnold, Germany; Antonia Digklya, Switzerland

10:30 - 10:50 **Fibrolamellar hepatocellular carcinoma: A rare variant of primary liver cancer**

Bruno Sangro, Clinica Universidad de Navarra, Pamplona, Spain

10:50 - 11:10 **Hereditary diffuse gastric cancer: From genetics to prevention**

Parry Guilford, University of Otago, Dunedin, New Zealand

11:10 - 11:30 **Gallbladder carcinoma: State-of-the-art**

Antonia Digklya, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

11:30 - 11:50 **Squamous rectal carcinoma**

Dirk Arnold, Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany

11:50 - 12:00 **Q&A and discussion**

**12:00 - 13:00 Type: Lunch break  
Title: Lunch**

**Foyer Ground Floor**



<b>12:15 - 13:00</b>	<b>Type: Young Oncologists session</b> <b>Title: YO Mentorship sessions</b> Moderation: Pawel Sobczuk, Poland; Christoph Oing, United Kingdom	<b>Foyer Asilo Ciani</b>
12:15 - 12:15	<b>How to set up your first clinical trial</b> <u>Sandra Strauss</u> , University College London Hospitals NHS Foundation Trust, London, United Kingdom	
12:15 - 12:15	<b>Finding and making use of mentorship</b> <u>Rick L. Haas</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
12:15 - 12:15	<b>How to successfully publish rare tumour research</b> <u>Suzanne George</u> , Dana Farber Cancer Institute, Boston, MA, United States of America	
<b>13:00 - 14:00</b>	<b>Type: Industry satellite symposium</b> <b>Title: Deciphera Pharmaceuticals - Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes</b> Moderation: Peter Reichardt, Germany	<b>Hall B1</b>
13:00 - 13:08	<b>Welcome and introduction</b> <u>Peter Reichardt</u> , Helios Klinikum Berlin-Buch, Berlin, Germany	
13:08 - 13:20	<b>Evolution of the role of local therapies for the treatment of GIST &amp; TGCT</b> <u>Alessandro Gronchi</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
13:20 - 13:32	<b>Unmet need and changing treatment landscape for TGCT patients</b> <u>Hans Gelderblom</u> , LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands	
13:32 - 13:44	<b>Overview of the recent changes and remaining unmet needs in GIST</b> <u>Axel Le Cesne</u> , Gustave Roussy - Cancer Campus, Villejuif, CEDEX, France	
13:44 - 13:55	<b>Q&amp;A</b>	
13:55 - 14:00	<b>Closing remarks</b> <u>Peter Reichardt</u> , Helios Klinikum Berlin-Buch, Berlin, Germany	



**14:15 - 15:45**    **Type: Educational session**    **Hall A**  
**Title: STS: Unsolved questions**  
Moderation: Maud Toulmonde, France; Dario Callegaro, Italy

14:15 - 14:35    **Therapeutic strategies for metastatic sarcoma based on NGS report**  
Ingrid Desar, Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands

14:35 - 14:55    **Novel tools for selecting patients for adjuvant therapy**  
Dario Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

14:55 - 15:15    **Is there a role for immune therapy for sarcomas in 2024?**  
Maud Toulmonde, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, CEDEX, France

15:15 - 15:35    **Is there a role for locoregional consolidation for residual metastatic disease after chemotherapy?**  
Waisse Waissi, Centre Léon Bérard, Lyon, CEDEX, France

15:35 - 15:45    **Q&A and discussion**

**14:15 - 15:45**    **Type: Educational session**    **Hall B1**  
**Title: The cross-border rare cancer patient: Where are we in the EU right now?**  
Moderation: Paolo G. Casali, Italy; Teodora Lalova-Spinks, Belgium

14:15 - 14:35    **Enabling cross-border healthcare: The EU Health Data Space**  
Annalisa Trama, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

14:35 - 14:55    **How to overcome constraints to cross-border healthcare in the EU?**  
Francesco De Lorenzo, ECPC - European Cancer Patient Coalition, Brussels, Belgium

14:55 - 15:15    **How to enable patients to access clinical trials across EU borders?**  
Teodora Lalova-Spinks, KU Leuven, Leuven, Belgium

15:15 - 15:35    **Virtual teleconsultations: A real-world classification attempt**  
Paolo G. Casali, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

15:35 - 15:45    **Q&A and discussion**



<b>14:15 - 15:25</b>	<b>Type: Young Oncologists session</b> <b>Title: YO Clinical Case Discussion</b> Moderation: Pawel Sobczuk, Poland; Christoph Oing, United Kingdom	<b>Hall B3</b>
14:15 - 14:25	<b>New molecular entity in a thoracic tumour: Diagnosis and treatment dilemmas</b> <u>Ana Sophie Terglav</u> , Institute of Oncology Ljubljana, Ljubljana, Slovenia	
14:25 - 14:35	<b>Discussion</b> <u>Herbert Ho Fung Loong</u> , The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong PRC	
14:35 - 14:45	<b>Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: A case report</b> <u>Andrea Franza</u> , Università degli Studi di Milano, Milan, Italy	
14:45 - 14:55	<b>Discussion</b> <u>Armelle Dufresne</u> , Centre Léon Bérard, Lyon, CEDEX 3, France	
14:55 - 15:05	<b>Capmatinib in patient with astrocytoma grade 4 IDH mutation and MET exon 4 skipping mutation</b> <u>David Dufek</u> , Masaryk Memorial Cancer Institute, Brno, Czech Republic	
15:05 - 15:15	<b>Discussion</b> <u>Christoph Oing</u> , Newcastle University, Newcastle upon Tyne, United Kingdom	
15:15 - 15:25	<b>Q&amp;A</b>	
<b>15:45 - 16:15</b>	<b>Type: Coffee break</b> <b>Title: Coffee break</b>	<b>Foyer Ground Floor</b>
<b>16:15 - 17:45</b>	<b>Type: Abstract session</b> <b>Title: Proffered Paper session 2</b> Moderation: Jean-Yves Blay, France; Claudia María Valverde Morales, Spain	<b>Hall A</b>
16:15 - 16:25	<b>550 - IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse</b> <u>Axel Le Cesne</u> <sup>1</sup> ; S. Chabaud <sup>2</sup> ; O. Bouche <sup>3</sup> ; N. Penel <sup>4</sup> ; M. Brahmi <sup>5</sup> ; M. Toulmonde <sup>6</sup> ; E. Bompas <sup>7</sup> ; F. Bertucci <sup>8</sup> ; L. Chaigneau <sup>9</sup> ; W. Lahlou <sup>10</sup> ; B. Landi <sup>10</sup> ; B. Verret <sup>11</sup> ; C. Henon <sup>12</sup> ; D. Pannier <sup>13</sup> ; M. Pracht <sup>14</sup> ; O. Collard <sup>15</sup> ; I. Ray-Coquard <sup>5</sup> ; S. Metzger <sup>16</sup> ; D. Perol <sup>5</sup> ; J.-Y. Blay <sup>17</sup> , <sup>1</sup> Gustave Roussy - Cancer Campus, Villejuif, CEDEX, France, <sup>2</sup> Centre de recherche en cancerologie de Lyon (CRCL), Lyon, France, <sup>3</sup> Hopital Robert Debré - CHU de Reims, Reims, France, <sup>4</sup> Centre Oscar Lambret, Lille, CEDEX, France, <sup>5</sup> Centre Léon Bérard, Lyon, CEDEX, France, <sup>6</sup> Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, CEDEX, France, <sup>7</sup> ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, CEDEX, France, <sup>8</sup> IPC - Institut Paoli-Calmettes, Marseille, France, <sup>9</sup> CHRU Besancon - Hopital Jean Minjot, Besancon, France, <sup>10</sup> HEGP -	





Hopital Europeen Georges-Pompidou - AP-HP, Paris, France, <sup>11</sup>Institut Gustave Roussy, Villejuif, France, <sup>12</sup>Institut Gustave Roussy, Villejuif, Cedex, France, <sup>13</sup>Centre Oscar Lambret, Lille, France, <sup>14</sup>Centre Eugene - Marquis, Rennes, CEDEX, France, <sup>15</sup>Hopital Privé de la Loire, Saint Etienne, France, <sup>16</sup>Center Leon Berard, Lyon, France, <sup>17</sup>Centre Léon Bérard, Lyon, France

- 16:25 - 16:35 **560 - A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma**  
P. Schöffski<sup>1</sup>; Peter Reichardt<sup>2</sup>; P. Lorusso<sup>3</sup>; N. Yamamoto<sup>4</sup>; L. Schwartz<sup>5</sup>; L. Dercle<sup>6</sup>; B. Zhao<sup>5</sup>; R. Chitalia<sup>7</sup>; G. Montgomery<sup>7</sup>; C. Hu<sup>8</sup>; H. Landsteiner<sup>9</sup>; G. Jayadeva<sup>8</sup>; M. Gounder<sup>5</sup>, <sup>1</sup>University Hospitals Leuven, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium, <sup>2</sup>Helios Klinikum Berlin-Buch, Berlin, Germany, <sup>3</sup>Yale Cancer Center, New Haven, CT, United States of America, <sup>4</sup>National Cancer Center Hospital, Tokyo, Japan, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, NY, United States of America, <sup>6</sup>Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, United States of America, <sup>7</sup>Invicro, Needham, MA, United States of America, <sup>8</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States of America, <sup>9</sup>Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria
- 16:35 - 16:45 **Invited Discussant abstracts 550 and 560**  
Cesar Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Barcelona, Spain
- 16:45 - 16:55 **Q&A and discussion**
- 16:55 - 17:05 **400 - Diagnostic trajectories of rare cancer patients in the Netherlands: Results from a nationwide cross-sectional survey**  
C. Simoes Padilla<sup>1</sup>; E. De Heus<sup>2</sup>; M. Reuvers<sup>1</sup>; M. Schrieks<sup>3</sup>; V. Engelen<sup>3</sup>; D. Gruenhagen<sup>4</sup>; M. Tesselaar<sup>1</sup>; W. Van Der Graaf<sup>1</sup>; S. Duijts<sup>2</sup>; Olga Husson<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, <sup>2</sup>IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands, <sup>3</sup>NFK - Dutch Federation of Cancer Patient Organisations, Utrecht, Netherlands, <sup>4</sup>Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
- 17:05 - 17:15 **1460 - Measuring health-related quality of life in solid rare cancer patients according to EURACAN domains: A progress report of an EORTC Quality of Life group (QLG) study**  
Catarina Simoes Padilla; O. Husson; W. Van Der Graaf; M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 17:15 - 17:25 **510 - The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research &#x2013; Insights from the EPIC Rare Cancers Working Group**  
Matthieu Foll<sup>1</sup>; C. Voegele<sup>1</sup>; B. Hemon<sup>1</sup>; M. Gunter<sup>2</sup>; P. Ferrari<sup>1</sup>; A. Trama<sup>3</sup>; N. Alcalá<sup>1</sup>; L. Fernandez-Cuesta<sup>1</sup>, <sup>1</sup>IARC - International Agency for Research on Cancer, Lyon, France,



<sup>2</sup>Imperial College London - South Kensington Campus, London, United Kingdom,  
<sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

17:25 - 17:35 **Invited Discussant abstracts 400, 1460 and 510**  
Joanna Szkandera, Medical University Graz-Center for Medical Research, Graz, Austria

17:35 - 17:45 **Q&A and discussion**

**18:00 - 19:00** **Type: Industry satellite symposium** **Hall B1**  
**Title: Servier - Search, find and rescue: Current science and future opportunities targeting IDH mutations in cancer**  
Moderation: Teresa Macarulla Mercade, Spain

18:00 - 18:05 **Introduction**  
Teresa Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, Spain

18:05 - 18:20 **IDH: A rare mutation in common cancers**  
Teresa Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, Spain

18:20 - 18:35 **IDH: A common mutation in a rare cancer**  
Ghazaleh Tabatabaj, Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, Germany

18:35 - 18:50 **IDH mutation: Focus on chondrosarcoma**  
Silvia Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

18:50 - 19:00 **Q&A and conclusion**  
Teresa Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, Spain



15.03.2024

**08:30 - 10:00**    **Type: Educational session**    **Hall A**  
**Title: GIST**  
Moderation: Cesar Serrano, Spain; Ingrid Desar, Netherlands

08:30 - 08:50    **What is the optimal duration of adjuvant treatment?**  
Nadia Hindi Muñiz, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

08:50 - 09:10    **What is the value of ctDNA?**  
Cesar Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Barcelona, Spain

09:10 - 09:30    **New drugs in development**  
Ingrid Desar, Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands

09:30 - 09:50    **Where to go next?**  
George Demetri, Dana Farber Cancer Institute, Boston, MA, United States of America

09:50 - 10:00    **Q&A and discussion**

**08:30 - 10:00**    **Type: Educational session**    **Hall B1**  
**Title: Thoracic cancers**  
Moderation: Nicolas Girard, France; Anne-Marie Dingemans, Netherlands

08:30 - 08:50    **Cardiac malignancies**  
Nicolas Girard, Institut Curie, Paris, France

08:50 - 09:10    **Large cell neuroendocrine carcinoma**  
Anne-Marie Dingemans, Erasmus MC - University Medical Center, Rotterdam, Netherlands

09:10 - 09:30    **Thoracic NUT and BRG1 deficient tumours**  
Benjamin Besse, Institut Gustave Roussy, Villejuif, Cedex, CEDEX, France

09:30 - 09:50    **Mediastinal germ cell tumours**  
Christoph Oing, Newcastle University, Newcastle upon Tyne, United Kingdom

09:50 - 10:00    **Q&A and discussion**



**08:30 - 10:00**    **Type: Educational session**    **Hall B3**  
**Title: New EU pharma regulation**  
Moderation: E.G. Elisabeth de Vries, Netherlands; Olli Tenhunen, Finland

08:30 - 08:50    **HTA**  
E.G. Elisabeth De Vries, UMCG - University Medical Center Groningen, Groningen, Netherlands

08:50 - 09:10    **Specific tools for rare cancers**  
Silvia Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

09:10 - 09:30    **MCBS, ESCAT and evaluation of clinical benefit and molecular targets in MAs and HTA**  
Olli Tenhunen, Finnish Medicines Agency, Oulu, Finland

09:30 - 09:50    **Expectations of the patients**  
Pan Pantziarka, Anticancer Fund, Strombeek-Bever, Belgium

09:50 - 10:00    **Q&A and discussion**

**10:00 - 10:30**    **Type: Coffee break**    **Foyer Ground Floor**  
**Title: Coffee break**



<b>10:30 - 12:00</b>	<b>Type: Educational session</b> <b>Title: ESMO Clinical Practice Guidelines</b> Moderation: Jean-Yves Blay, France; Claudia María Valverde Morales, Spain	<b>Hall A</b>
10:30 - 10:36	<b>Introduction</b> <u>Claudia María Valverde Morales</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
10:36 - 10:46	<b>Clinical case: Breast malignant phyllodes tumour</b> <u>Carmine Valenza</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy	
10:46 - 10:56	<b>Discussant</b> <u>Jean-Yves Blay</u> , Centre Léon Bérard, Lyon, CEDEX, France	
10:56 - 11:04	<b>Q&amp;A and discussion</b>	
11:04 - 11:14	<b>Clinical case: Uveal melanoma</b> <u>Emanuel Gouveia</u> , Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal	
11:14 - 11:24	<b>Discussant</b> <u>Sophie Piperno-Neumann</u> , Institut Curie, Paris, CEDEX 5, France	
11:24 - 11:32	<b>Q&amp;A and discussion</b>	
11:32 - 11:42	<b>Clinical case: Nasopharyngeal carcinoma</b> <u>Riccardo Gili</u> , IRCCS Ospedale Policlinico San Martino, Genova, Italy	
11:42 - 11:52	<b>Discussant</b> <u>Amanda Psyrri</u> , Attikon University Hospital, Haidari, Greece	
11:52 - 12:00	<b>Q&amp;A and discussion</b>	



**10:30 - 12:00**    **Type: Educational session**    **Hall B1**  
**Title: CNS**  
 Moderation: Khe Hoang-Xuan, France; Giuseppe Lombardi, Italy

10:30 - 10:45    **Pineal region tumours**  
Giuseppe Lombardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy

10:45 - 11:00    **Primary CNS lymphoma**  
Khe Hoang-Xuan, Assistance Publique - Hopitaux De Paris, Paris, France

11:00 - 11:15    **Ependymal tumours**  
Marica Eoli, Fondazione IRCCS - Istituto Neurologico C.Besta, Milan, Italy

11:15 - 11:30    **Rare pituitary tumours**  
Laetitia Lebrun, Erasme Hospital - Universite Libre de Bruxelles (ULB), Brussels, Belgium

11:30 - 11:40    **10 - Extended dosing vs conventional dosing of adjuvant temozolomide in adults with newly diagnosed high grade gliomas: A randomized, single-blind, two-arm, parallel-group controlled trial**  
Seyed Alireza Javadinia<sup>1</sup>; K. Anvari<sup>2</sup>; M. Seilanian Toussi<sup>3</sup>; M. Saghafi<sup>4</sup>; H. Saghafi<sup>5</sup>; J. Welsh<sup>6</sup>, <sup>1</sup>Vasei Hospital, Sabzevar, Iran, <sup>2</sup>Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi, Iran, <sup>3</sup>Mashhad University of Medical Sciences, Mashhad, Iran, <sup>4</sup>Qazvin University of Medical Sciences, Mashhad, Iran, <sup>5</sup>Tehran University of Medical Sciences - School of Medicine, Tehran, Iran, <sup>6</sup>Loyola University Chicago, Chicago, United States of America

11:40 - 11:45    **Invited Discussant abstract 10**  
Ahmed Idbaih, Hopital Pitié Salpêtrière AP-HP, Paris, France

11:45 - 12:00    **Q&A and discussion**

**12:00 - 13:00**    **Type: Poster Display session**    **Foyer Ground Floor**  
**Title: Poster Display session**

12:00 - 12:00    **Central Nervous System (CNS)**

12:00 - 13:00    **2P - Eye-sparing management of retinoblastoma: Survival analysis and the risk of multiple primary malignancies**  
 F. Elawady Elgharib<sup>1</sup>; Asmaa Ellaithy<sup>2</sup>; R. Abdelkareem<sup>1</sup>, <sup>1</sup>Port Said Specialized Hospital of Ophthalmology, Port Fuad, Egypt, <sup>2</sup>Suez Canal University Hospital, Ismailia, Egypt

13:00 - 14:00    **4P - Prognostic value of systemic inflammatory markers in GBM: Multicenter retrospective study**



M.J. Ramos<sup>1</sup>; C. Oliveira<sup>2</sup>; A. Fortuna<sup>3</sup>; Emanuel Ferreira<sup>4</sup>; M. Falcão<sup>4</sup>; A. Mendes<sup>1</sup>; M. Magalhaes<sup>1</sup>; E. Rosendo<sup>1</sup>; A. Araujo<sup>1</sup>, <sup>1</sup>Centro Hospitalar Universitario de Santo Antonio, Porto, Portugal, <sup>2</sup>Hospital de Braga EPE - SNS, Braga, Portugal, <sup>3</sup>Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, Portugal, <sup>4</sup>Centro Hospitalar Tras-os-Montes e Alto Douro, EPE-SNS, Vila Real, Portugal

14:00 - 15:00 **5P - IDH1 mutation status and overall survival in glioblastoma patients: A meta-analysis**

R. Alshimi<sup>1</sup>; R. Odat<sup>1</sup>; Zaid Shakhathreh<sup>2</sup>; A. Abdallah<sup>3</sup>; A. Alomari<sup>4</sup>, <sup>1</sup>Jordan University of Science and Technology, IRBID, Jordan, <sup>2</sup>Jordan University of Science and Technology, Irbid, Jordan, <sup>3</sup>King Abdullah University Hospital, Irbid, Jordan, <sup>4</sup>Division of Neurosurgery, Faculty of Medicine, Mutah University, Al-Karak, Jordan

15:00 - 16:00 **6P - Extraosseous central nervous system Ewing sarcoma: A single-center retrospective case series**

Florencia Yorio<sup>1</sup>; N. Arakaki<sup>2</sup>; L. Alessandro<sup>1</sup>; N. Palomar<sup>1</sup>; B. Diez<sup>3</sup>; A. Muggeri<sup>4</sup>, <sup>1</sup>FLENI - Sede Belgrano, Buenos Aires, Argentina, <sup>2</sup>FLENI, Buenos Aires, Argentina, <sup>3</sup>FLENI, BUENOS AIRES, Argentina, <sup>4</sup>FLENI - Sede Belgrano, Buenos Aires, Buenos Aires, Argentina

16:00 - 16:00 **Digestive cancers**

16:00 - 17:00 **7P - Feasibility, toxicity and clinical outcomes of carboplatin and paclitaxel induction chemotherapy in advanced anal cancer**

M. Temnyk; K. Pędziwiatr; M. Gidzińska-Wielgosz; Lucjan Wyrwicz, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

17:00 - 18:00 **8P - Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma**

Asmaa Ellaithy, Suez Canal University, Ismailia, Egypt

18:00 - 19:00 **10P - The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000&#x2013;2013;2020**

W. Yahya<sup>1</sup>; Asmaa Ellaithy<sup>2</sup>, <sup>1</sup>Benghazi University, benghazi, Libya, <sup>2</sup>Suez Canal University Hospital, Ismailia, Egypt

19:00 - 19:00 **Genitourinary cancers**

19:00 - 20:00 **11P - Impact of testicular cancer on socio-economic and sexual health of survivors: A questionnaire-based survey**

Muhammad Khan<sup>1</sup>; P. Kearney Sheehan<sup>1</sup>; A. Bazin<sup>2</sup>; C. Leonard<sup>3</sup>; U. Aleem<sup>4</sup>; L. Corrigan<sup>1</sup>; R.S. Mcdermott<sup>2</sup>, <sup>1</sup>Tallaght University Hospital, Dublin, Ireland, <sup>2</sup>AMNCH Adelaide and Meath Hospital, Dublin, Belgard Square North, Ireland, <sup>3</sup>AMNCH Adelaide and Meath Hospital, Dublin, Ireland, <sup>4</sup>The Christie NHS Foundation Trust, Manchester, United Kingdom



- 20:00 - 21:00 **12P - Do retroperitoneal extragonadal germ cell tumours (pR-GCT) exist? Evaluation of treatment outcomes of an international retrospective collaboration (PRIMERE study-IGG05)**  
Chiara Cavalli<sup>1</sup>; E. Gusmaroli<sup>1</sup>; I. Tagliatela<sup>1</sup>; M. Mego<sup>2</sup>; D. Bimbatti<sup>3</sup>; S. Secondino<sup>4</sup>; D. BIASONI<sup>1</sup>; M. Catanzaro<sup>1</sup>; M. Claps<sup>1</sup>; M. Zimatore<sup>1</sup>; T. Torelli<sup>1</sup>; S. Stagni<sup>1</sup>; A. Macchi<sup>1</sup>; A. Tesone<sup>1</sup>; P. Pedrazzoli<sup>4</sup>; U. Basso<sup>5</sup>; G. Procopio<sup>1</sup>; N. Nicolai<sup>1</sup>; P. Giannatempo<sup>1</sup>,  
<sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, <sup>2</sup>National Cancer Institute of Slovakia, Bratislava, Slovak Republic, <sup>3</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy, <sup>4</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>5</sup>ISTITUTO ONCOLOGICO VENETO IOV - IRCCS, PADOVA, Italy
- 21:00 - 22:00 **13P - First-line CEMiplimab in metastatic PENile squamous cell carcinoma: The CemPen study**  
Elisabetta Gambale<sup>1</sup>; I.A. Vascotto<sup>1</sup>; G. Venturi<sup>1</sup>; I. De Gennaro Aquino<sup>1</sup>; V. Rossi<sup>2</sup>; M.M. Mela<sup>2</sup>; E. Caliman<sup>1</sup>; S. Fancelli<sup>1</sup>; F. Scolari<sup>1</sup>; S. Pillozzi<sup>2</sup>; L. Doni<sup>2</sup>; C. Carella<sup>3</sup>; M. De Tursi<sup>3</sup>; L. Antonuzzo<sup>1</sup>, <sup>1</sup>UNIFI - Università degli Studi di Firenze - DMSC, Firenze, Italy, <sup>2</sup>Azienda Ospedaliera Careggi U.O. Oncologia Medica, Firenze, Italy, <sup>3</sup>Ospedale Clinicizzato SS. Annunziata - Chieti - Policlinico, Chieti, Italy
- 22:00 - 22:00 **Gynaecological cancers**
- 22:00 - 23:00 **15P - Clinicopathological characteristics and prognostic factors in malignant struma ovarii: A multivariate analysis**  
Sakhr Alshwayyat<sup>1</sup>; M. Alshwayyat<sup>1</sup>; T. Yaser Dabash<sup>1</sup>; D.E. Abo-Elnour<sup>2</sup>; T. Alshwayyat<sup>1</sup>,  
<sup>1</sup>JUST - Jordan University of Science and Technology, Irbid, Jordan, <sup>2</sup>Zagazig University Faculty of Medicine, Zagazig, Egypt
- 23:00 - 00:00 **16P - Granulosa cell tumor of the ovary: 10-year follow-up data of 56 patients**  
Ash Geçgel; O. Özkan; S.B. Karaca Yayla; E. Goker; U.A. Sanli, Ege University - Faculty of Medicine, Izmir, Turkey
- 00:00 - 01:00 **17P - Gynaecologic carcinosarcomas (GCS)&#x2019;s chemotherapy landscape: A retrospective analysis from Hospital Clinico San Carlos (HCSC), academic, referral centre for rare gynaecological malignancies in Madrid (Spain)**  
Beatriz Diez<sup>1</sup>; A. Casado Herraes<sup>2</sup>; A. Manzano Fernández<sup>2</sup>; P. Coronado<sup>2</sup>; J. Garcia Santos<sup>2</sup>; M. Ramirez<sup>2</sup>; M. Bellon<sup>2</sup>; R. Sanchez Del Hoyo<sup>2</sup>; A. Pascual<sup>2</sup>; C. Diaz Del Arco<sup>2</sup>; N. Sanmamed<sup>2</sup>; E. Cerezo<sup>2</sup>; R. Mendez<sup>2</sup>; M. Muñoz<sup>2</sup>; J.M. Espejo<sup>2</sup>; A. Nava<sup>2</sup>; C. Rodriguez<sup>2</sup>; A. Ortega<sup>2</sup>; G. Marquina<sup>2</sup>, <sup>1</sup>Hospital Clinico Universitario San Carlos, Madrid, Spain, <sup>2</sup>Hospital Clinico Universitario San Carlos, IdISCC, UCM, Madrid, Spain
- 01:00 - 02:00 **18P - Decoding the interplay of deubiquitinating enzymes (DUBs) in metastasis and chemoresistance of gynaecological cancers**  
Ravi Chauhan<sup>1</sup>; A. Gupta<sup>1</sup>; G. Dagar<sup>1</sup>; L. Malhotra<sup>2</sup>; S. De<sup>3</sup>; E.A. Samath<sup>1</sup>; N. Singh<sup>3</sup>; M. Singh<sup>1</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, India, <sup>2</sup>Sri Venkateswara College, University of Delhi, New Delhi, India, <sup>3</sup>Indian Institute of





Technology, New Delhi, India

- 02:00 - 03:00 **19P - Long-term fatigue after treatments for non-epithelial ovarian cancer survivors**  
C. Dubot<sup>1</sup>; I. Ray Coquard<sup>2</sup>; P. Pautier<sup>3</sup>; J. Lequesne<sup>4</sup>; T. Renaud<sup>5</sup>; F. Selle<sup>6</sup>; D. Berton-Rigaud<sup>7</sup>; S. Frank<sup>8</sup>; T. De La Motte Rouge<sup>9</sup>; E. Kalbacher<sup>10</sup>; M. Provansal Gross<sup>11</sup>; C. Blonz<sup>12</sup>; H. Orfeuvre<sup>13</sup>; J. Alexandre<sup>14</sup>; P. Augereau<sup>15</sup>; J.E. Kurtz<sup>16</sup>; J.-M. Grellard<sup>17</sup>; B. Clarisse<sup>18</sup>; F. Gernier<sup>17</sup>; Florence Joly Lobbedez<sup>18</sup>, <sup>1</sup>Clinical Research Department, Baclesse Cancer Centre ; INSERM, U1086, Caen, Cedex, France, <sup>2</sup>Centre Léon Bérard, Lyon, France, <sup>3</sup>Institut Gustave Roussy, Villejuif, Cedex, CEDEX, France, <sup>4</sup>Centre Francois Baclesse, Caen, France, <sup>5</sup>Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, France, <sup>6</sup>Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, CEDEX, France, <sup>8</sup>Institut Curie, Paris, CEDEX 10, France, <sup>9</sup>Centre Eugene - Marquis, Rennes, France, <sup>10</sup>Centre Jean PERRIN, Clermont-Ferrand, Cedex, CEDEX, France, <sup>11</sup>Institute Paoli Calmettes, Marseille, France, <sup>12</sup>Groupe Confluent, Rezé, France, <sup>13</sup>Ch Fleyriat, Bourg En Bresse, CEDEX, France, <sup>14</sup>Hopital Cochin - Site Port-Royal AP-HP, Paris, France, <sup>15</sup>Centre Paul Papin, Angers, France, <sup>16</sup>ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France, <sup>17</sup>Centre Francois Baclesse, Caen, Cedex, France, <sup>18</sup>Centre Francois Baclesse, Caen, Cedex, CEDEX 5, France
- 03:00 - 04:00 **20P - Outcome of neuroendocrine carcinoma of the cervix: A decade of experience at the National Cancer Institute, Malaysia**  
Rizma Mohd Zaid<sup>1</sup>; M.N. Mokhtar<sup>2</sup>, <sup>1</sup>National Cancer Institute, Putrajaya, Malaysia, <sup>2</sup>UKM - Universiti Kebangsaan Malaysia - Faculty of Medicine, Cheras, Malaysia
- 04:00 - 04:00 **Head and neck cancers**
- 04:00 - 05:00 **21P - Age-adjusted trends in patients with head and neck sarcomas**  
Amr Aly, Suez Canal University Hospital, Ismailia, Egypt
- 05:00 - 06:00 **23P - Preclinical evaluation of targeted agents alone or combined with chemotherapy in the adenoid cystic carcinoma cells**  
Andrea Abate<sup>1</sup>; T. Savarese<sup>1</sup>; R.M. Basnet<sup>1</sup>; L. Lorini<sup>2</sup>; C. Gurizzan<sup>3</sup>; M. Tomasoni<sup>3</sup>; D. Lombardi<sup>3</sup>; D. Mattavelli<sup>3</sup>; D. Tomasini<sup>3</sup>; D. Zizioli<sup>1</sup>; M. Memo<sup>1</sup>; A. Berruti<sup>3</sup>; S.A. Bonini<sup>1</sup>; C. Piazza<sup>3</sup>; P. Bossi<sup>4</sup>; S. Sigala<sup>1</sup>, <sup>1</sup>University of Brescia, Brescia, Italy, <sup>2</sup>Medical Oncology Unit, Rozzano, Italy, <sup>3</sup>University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>4</sup>IRCCS Humanitas Resear, Humanitas Universitych Hospital, Rozzano, Italy
- 06:00 - 07:00 **24P - Sinonasal neuroendocrine tumors: Analysis of therapeutic strategies in an ultra-rare tumor**  
S. Barriendos Sanz; N. Pascual De La Fuente; P. Mugarza; M.L. Monreal Cepero; S.E. Campos Ramirez; F. Mocha Campillo; P. Trincado Cobos; S.E. Ruffini Egea; A.M. Comín Orce; Javier Martinez Trufero, Hospital Universitario Miguel Servet, Zaragoza, Spain
- 07:00 - 08:00 **25P - Risk of second primary head and neck cancer in patients with head and neck soft tissue sarcoma**



Amr Aly, Suez Canal University Hospital, Ismailia, Egypt

08:00 - 08:00 **Neuroendocrine and Endocrine cancers**

08:00 - 09:00 **28P - Decoding biomarkers of immune activation in neuroendocrine carcinomas treated with ipilimumab and nivolumab using a multiomic approach**

Cara Haymaker<sup>1</sup>; G. Kumar<sup>1</sup>; Y.K. Chae<sup>2</sup>; E. Gonzalez-Kozlova<sup>3</sup>; C. Duault<sup>4</sup>; J. Zhang<sup>5</sup>; M. Othus<sup>6</sup>; L. Solis Soto<sup>5</sup>; G. Manyam<sup>5</sup>; P. Jiang<sup>7</sup>; E. Parra<sup>7</sup>; C. Laberiano Fernandez<sup>5</sup>; A. Reuben<sup>7</sup>; H. Maecker<sup>4</sup>; S. Gnjatic<sup>3</sup>; G. Al-Atrash<sup>1</sup>; J. Zhang<sup>7</sup>; J.J. Lee<sup>1</sup>; S. Patel<sup>8</sup>; R. Kurzrock<sup>9</sup>, <sup>1</sup>University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, United States of America, <sup>3</sup>Icahn School of Medicine at Mount Sinai, New York, United States of America, <sup>4</sup>Stanford University School of Medicine, Stanford, United States of America, <sup>5</sup>University of Texas MD Anderson Cancer Center, Houston, United States of America, <sup>6</sup>Fred Hutchinson Cancer Research Center, Seattle, United States of America, <sup>7</sup>MD Anderson Cancer Center, Houston, TX, United States of America, <sup>8</sup>UCSD Moores Cancer Center, La Jolla, CA, United States of America, <sup>9</sup>Froedtert Hospital & Medical College of Wisconsin, Milwaukee, TX, United States of America

09:00 - 09:20 **29P - First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study**

Jing Xu; D. Zhu; Z. Liu; J. Cui; M. Liu; W. Hu; H. Fu; J. Zhao; X. Fan, Shandong First Medical University Affiliated Cancer Hospital, Jinan, China

09:20 - 10:20 **30P - AI-based response monitoring in gastroenteropancreatic neuroendocrine tumors**

Kalina Chupetlovska<sup>1</sup>; J. Engel<sup>2</sup>; R. Beets-Tan<sup>1</sup>; M. Tesselaa<sup>1</sup>; M. Maas<sup>1</sup>; S. Trebeschi<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, <sup>2</sup>University of Twente, Enschede, Netherlands

10:20 - 11:20 **31P - Surgical and chemotherapeutic strategies for stage IV pancreatic neuroendocrine carcinoma according to the latest WHO classification**

Wentao Huang<sup>1</sup>; H. Asadi<sup>1</sup>; A. Tumati<sup>1</sup>; N. Salehi<sup>1</sup>; T. Marshall<sup>1</sup>; B. Greenspun<sup>1</sup>; B. Finnerty<sup>1</sup>; T. Fahey 3Rd<sup>1</sup>; F. Qiu<sup>2</sup>; R. Zarnegar<sup>1</sup>, <sup>1</sup>NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, NY, United States of America, <sup>2</sup>Fujian Provincial Hospital, Fuzhou, China

11:20 - 12:20 **32P - Clinical profile and presentation of patients with gastroenteropancreatic neuroendocrine neoplasms: An updated dataset from India**

Tanuj Chawla<sup>1</sup>; J. Ghosh<sup>2</sup>; S. Ganguly<sup>1</sup>; M. Mallath<sup>3</sup>, <sup>1</sup>TMC - Tata Medical Center, Kolkata, India, <sup>2</sup>Tata Medical Center, Kolkata, India, <sup>3</sup>TMC - Tata Medical Center, Kolkata, West Bengal, India

12:20 - 13:20 **33P - High-grade neuroendocrine neoplasms (NEN) and their different response to platinum according to anatomopathological classification**



Paloma Santos Fernandez; J. Sanz Repetto; E. Casaut Lora; S. Rubiales Trujillano, Hospital Universitario de Puerto Real, Puerto Real, Spain

- 13:20 - 14:20 **34P - Impact of environmental pollution on adrenocortical carcinoma in Italy**  
S. Puglisi<sup>1</sup>; A. Calabrese<sup>1</sup>; F. Ferrau<sup>2</sup>; M. Laganà<sup>3</sup>; S. Grisanti<sup>3</sup>; F. Ceccato<sup>4</sup>; C. Scaroni<sup>4</sup>; G. Di Dalmazi<sup>5</sup>; A. Stigliano<sup>6</sup>; B. Altieri<sup>7</sup>; L. Canu<sup>8</sup>; M. Luconi<sup>8</sup>; P. Loli<sup>9</sup>; M.C. De Martino<sup>10</sup>; E. Arvat<sup>11</sup>; S. Palmieri<sup>12</sup>; V. Basile<sup>1</sup>; Alfredo Berruti<sup>3</sup>; S. Cannavò<sup>2</sup>; M. Terzolo<sup>1</sup>, <sup>1</sup>University of Turin, Torino, Italy, <sup>2</sup>AOU Policlinico G. Martino - Università di Messina, Messina, Italy, <sup>3</sup>University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>4</sup>Azienda Universitaria Ospedaliera di Padova, Padova, Italy, <sup>5</sup>University of Bologna - Alma Mater Studiorum, Bologna, Italy, <sup>6</sup>Sapienza - Università di Roma, Rome, Italy, <sup>7</sup>Università Cattolica del Sacro Cuore, Roma, Italy, <sup>8</sup>Azienda Ospedaliera Careggi, Firenze, Italy, <sup>9</sup>Clinica Polispecialistica San Carlo s.r.l, Paderno Dugnano, Italy, <sup>10</sup>Università degli Studi di Napoli Federico II, Napoli, Italy, <sup>11</sup>Università di Torino, Torino, Italy, <sup>12</sup>Università degli Studi di Milano, Milan, Italy
- 14:20 - 15:20 **35P - ABACUS trial: Abiraterone acetate in the management of Cushing's syndrome associated to adrenocortical carcinoma**  
D. Cosentini<sup>1</sup>; S. Puglisi<sup>2</sup>; S. Grisanti<sup>1</sup>; V. Basile<sup>3</sup>; M. Laganà<sup>1</sup>; V. Ferrari<sup>4</sup>; A. Abate<sup>5</sup>; A. Calabrese<sup>3</sup>; E. Rossini<sup>5</sup>; G. Tiberio<sup>5</sup>; A. Pia<sup>2</sup>; S. Sigala<sup>5</sup>; M. Terzolo<sup>3</sup>; Alfredo Berruti<sup>1</sup>, <sup>1</sup>University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>2</sup>Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy, <sup>3</sup>University of Turin, Torino, Italy, <sup>4</sup>ASST Spedali Civili di Brescia, Brescia, Italy, <sup>5</sup>University of Brescia, Brescia, Italy
- 15:20 - 16:20 **36P - Progesterone and trabectedin activity in preclinical cell models of adrenocortical carcinoma**  
Andrea Abate<sup>1</sup>; M. Tamburello<sup>1</sup>; R.M. Basnet<sup>1</sup>; D. Zizioli<sup>1</sup>; M. Laganà<sup>2</sup>; D. Cosentini<sup>2</sup>; C. Hantel<sup>3</sup>; S. Grisanti<sup>2</sup>; G. Tiberio<sup>1</sup>; A. Berruti<sup>2</sup>; S. Sigala<sup>1</sup>, <sup>1</sup>University of Brescia, Brescia, Italy, <sup>2</sup>University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>3</sup>University Hospital Zurich (USZ) and University of Zurich (UZH), Schlieren, Switzerland
- 16:20 - 17:20 **37P - Estrogen-mimetic effects of mitotane in patients with adrenocortical carcinoma: Focus on this neglected toxicity**  
Antonella Turla<sup>1</sup>; M. Laganà<sup>1</sup>; V. Cremaschi<sup>1</sup>; B. Trevisan<sup>1</sup>; A. Abate<sup>2</sup>; M. Tamburello<sup>2</sup>; S. Sigala<sup>2</sup>; D.L. Bettini<sup>1</sup>; S. Grisanti<sup>1</sup>; A. Gambino<sup>2</sup>; G. Tognon<sup>2</sup>; D. Cosentini<sup>1</sup>; A. Berruti<sup>1</sup>, <sup>1</sup>University of Brescia, ASST Spedali Civili, Brescia, Italy, <sup>2</sup>University of Brescia, Brescia, Italy
- 17:20 - 18:20 **38P - Venous thromboembolism in patients with adrenocortical carcinoma: A multicentre retrospective study**  
Benedetta Trevisan<sup>1</sup>; O. Kimpel<sup>2</sup>; S. Puglisi<sup>3</sup>; R. Steenaard<sup>4</sup>; M.C. Fragoso<sup>5</sup>; L. Menezes<sup>5</sup>; J. Crona<sup>6</sup>; D. Cosentini<sup>7</sup>; H. Haak<sup>8</sup>; M. Terzolo<sup>3</sup>; M. Fassnacht<sup>9</sup>; M. Laganà<sup>1</sup>; A. Berruti<sup>7</sup>, <sup>1</sup>ASST Spedali Civili di Brescia, Brescia, Italy, <sup>2</sup>UKW - University Hospital Würzburg, Würzburg, Germany, <sup>3</sup>University of Turin, Torino, Italy, <sup>4</sup>Máxima MC, Eindhoven/Veldhoven, Eindhoven, Netherlands, <sup>5</sup>ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil, <sup>6</sup>Akademiska Sjukhuset, Uppsala, Sweden, <sup>7</sup>Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy, <sup>8</sup>Maxima MC Eindhoven, Eindhoven, Netherlands, <sup>9</sup>University Hospital Würzburg, Würzburg, Germany



18:20 - 18:20 **Public Policy and Patient Advocacy**

18:20 - 19:20 **41P - Assessment of rare cancers and sarcoma policy in National Cancer Control Plans (NCCPs) from South American countries: A report from the LACOG Sarcoma Group**

Roberto Carmagnani Pestana<sup>1</sup>; D. Silva<sup>2</sup>; R. Schmerling<sup>3</sup>; R. Zon Filippi<sup>4</sup>; B. Lopes David<sup>5</sup>; V. Pires De Camargo<sup>6</sup>; C. Mello<sup>7</sup>; M. Gonzalez Donna<sup>8</sup>; R. Ramella Munhoz<sup>9</sup>; J. Haro Varas<sup>10</sup>; M. Zapata<sup>11</sup>; C. Martins<sup>12</sup>; M. Chacon<sup>13</sup>; R. Jesus-Garcia<sup>4</sup>, <sup>1</sup>Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, Sao Paulo, Brazil, <sup>2</sup>Albert Einstein Israelite Hospital, Sao Paulo, Brazil, <sup>3</sup>HCOR, São Paulo, Brazil, <sup>4</sup>Hospital Israelita Albert Einstein, São Paulo, Brazil, <sup>5</sup>INCA - Instituto Nacional de Cancer José Alencar Gomes da Silva, Rio de Janeiro, Brazil, <sup>6</sup>Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo, Brazil, <sup>7</sup>AC Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Sao Paulo, Brazil, <sup>8</sup>INCAN - Instituto Nacional del Cancer, Capiata, Paraguay, <sup>9</sup>Hospital Sirio Libanes - Complexo Hospitalar Bela Vista, Sao Paulo, SP, Brazil, <sup>10</sup>INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, <sup>11</sup>Clinica Las Americas - Instituto de Cancerologia, Medellin, Colombia, <sup>12</sup>Americas Centro de Oncologia Integrado, Rio de Janeiro, Brazil, <sup>13</sup>Instituto Alexander Fleming, Buenos Aires, Argentina

19:20 - 20:20 **43P - Pathway of patients with rare liver tumors: From the first hospital visit to the definitive treatment in a specialized center**

Maria Bilych<sup>1</sup>; A. Grinenko<sup>1</sup>; O. Zotov<sup>2</sup>; J. Zaivelieva<sup>3</sup>; D. Fedorov<sup>4</sup>; V. Kropelnytskyi<sup>1</sup>, <sup>1</sup>National Scientific Center of Surgery and Transplantation Named after O.O. Shalimov to National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine, <sup>2</sup>NMU - National Medical University named after O.O. Bogomolets, Kiev, Ukraine, <sup>3</sup>O.O. Shalimov`s National Institute of Surgery and Transplantation, Kyiv, Ukraine, <sup>4</sup>A.A. Shalimov National Institute of Surgery and Transplantology, Kiev, Ukraine

20:20 - 21:20 **44P - "Am I rare?" "Am I rare?"; "Am I rare?"; Patient awareness is the first step in building an adequate treatment path: A survey on neuroendocrine tumors**

Silvia Della Torre<sup>1</sup>; V. Smiroldo<sup>2</sup>; C. Cozzi<sup>1</sup>; R. Bollina<sup>1</sup>, <sup>1</sup>Ospedale G. Salvini - ASST Rhodense, Rho, Italy, <sup>2</sup>Asst-Rhodense, Rho, Italy

21:20 - 22:20 **45P - The patient voices: Revealing the challenges faced by persons with desmoid tumors in a middle-income country**

Carolina Menezes Chaves<sup>1</sup>; P. Apolinario Costa<sup>2</sup>; L. Prudente Barbieri<sup>1</sup>; B. Lopes David<sup>3</sup>; C. Lopes De Mello<sup>4</sup>; F. Campos<sup>5</sup>; G. Mounssef<sup>1</sup>, <sup>1</sup>ABTD - Desmoide Brasil, Sao Paulo, Brazil, <sup>2</sup>Yale School of Medicine, New Haven, Brazil, <sup>3</sup>INCA - Instituto Nacional de Cancer José Alencar Gomes da Silva, Rio de Janeiro, Brazil, <sup>4</sup>A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, SP, Brazil, <sup>5</sup>A.C. Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Sao Paulo, Brazil

22:20 - 23:19 **46P - The pre-diagnostic general practitioner care of sarcoma patients: A real-world data study**



Emily Holthuis<sup>1</sup>; W. Van Der Graaf<sup>1</sup>; C. Drabbe<sup>2</sup>; W. Van Houdt<sup>1</sup>; Y. Schrage<sup>3</sup>; A.M. Koenen<sup>1</sup>; S. Van Der Kleij<sup>1</sup>; T. Olde Hartman<sup>2</sup>; A. Uijen<sup>2</sup>; I. Bos<sup>4</sup>; M. Heins<sup>4</sup>; O. Husson<sup>1</sup>,  
<sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, <sup>2</sup>Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, <sup>3</sup>Leiden University Medical Center (LUMC), Leiden, Netherlands, <sup>4</sup>Netherlands Institute for Health Services Research (Nivel), Utrecht, Netherlands

23:19 - 00:19 **47P - Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes**

Dagmar Adamkova<sup>1</sup>; K. Kopeckova<sup>2</sup>; J. Muzik<sup>3</sup>; L. Dusek<sup>3</sup>; R. Simunek<sup>1</sup>; J. Halamkova<sup>1</sup>; I. Kiss<sup>4</sup>; L. Kristková<sup>1</sup>, <sup>1</sup>Masaryk Memorial Cancer Institute, Brno, Czech Republic, <sup>2</sup>Motol University Hospital, Prague, 5, Czech Republic, <sup>3</sup>Institute of Health Information and Statistics of the Czech Republic, Prag, Czech Republic, <sup>4</sup>Masaryk Memorial Cancer Institute, Brno, South Moravian, Czech Republic

00:19 - 01:19 **48P - Delay of imaging studies in patients with newly diagnosed sarcoma**

Lauren Li; N. Bui; K. Ganjoo; M. Pan, Stanford University, PALO ALTO, CA, United States of America

01:19 - 02:19 **49P - The impact of unplanned excision &#x2018;whoops surgery&#x2019; with or without surgery in outcome of trunk and extremity soft tissue sarcoma patients: A retrospective analysis**

Mohamed Kelany<sup>1</sup>; A. Gaballah<sup>2</sup>; M. M. Hussien.<sup>2</sup>; A. Nofal<sup>2</sup>; N. Gad<sup>3</sup>, <sup>1</sup>Ain Shams University Hospital - Faculty of Clinical Medicine and Radiation Oncology, Cairo, Egypt, <sup>2</sup>Ain Shams University - Faculty of medicine, Cairo, Egypt, <sup>3</sup>Ain Shams University - Faculty of Medicine, Cairo, Egypt

02:19 - 03:19 **50P - The difficulties associated with handling bone sarcoma in the northern region of Morocco**

Niama Ghozali; S. Yassine; M. Amzerin; K. Darif; F.Z. El M'Rabet; B. Cherradi; M. Taire; H. El Bakouri; A. Gourinda, Tangier Oncology Center, Tangier, Morocco

03:19 - 03:19 **Sarcoma**

03:19 - 04:19 **62P - Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 &#x2b; 17/18 mutations: ctDNA analysis from INTRIGUE**

Jean-Yves Blay<sup>1</sup>; R. Jones<sup>2</sup>; H. Gelderblom<sup>3</sup>; S. George<sup>4</sup>; P. Schöffski<sup>5</sup>; M. Von Mehren<sup>6</sup>; J. Zalcberg<sup>7</sup>; Y.-K. Kang<sup>8</sup>; A.R. Abdul Razak<sup>9</sup>; J. Trent<sup>10</sup>; S. Attia<sup>11</sup>; A. Le Cesne<sup>12</sup>; E. Davis<sup>13</sup>; K. Sprott<sup>13</sup>; P. Cox<sup>13</sup>; M. Sherman<sup>13</sup>; R. Ruiz-Soto<sup>13</sup>; M. Heinrich<sup>14</sup>; S. Bauer<sup>15</sup>,  
<sup>1</sup>Centre Léon Bérard, Lyon, CEDEX, France, <sup>2</sup>Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, WA, United Kingdom, <sup>3</sup>Leiden University Medical Center, Leiden, Netherlands, <sup>4</sup>Dana-Farber Cancer Institute, Boston, MA, United States of America, <sup>5</sup>University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium, <sup>6</sup>Fox Chase Cancer Center - Temple University Health System, Philadelphia, PA, United States of America, <sup>7</sup>Monash University School of



Public Health and Preventive Medicine and Alfred Health, Melbourne, VIC, Australia, <sup>8</sup>Asan Medical Center, University of Ulsan, Seoul, Songpa-gu, Korea, Republic of, <sup>9</sup>Princess Margaret Cancer Centre, Toronto, Canada, <sup>10</sup>Sylvester Comprehensive Cancer Center and University of Miami Health System, Miami, FL, United States of America, <sup>11</sup>Mayo Clinic, Jacksonville, FL, United States of America, <sup>12</sup>Gustave Roussy, Villejuif, CEDEX, France, <sup>13</sup>Deciphera Pharmaceuticals, LLC, Waltham, MA, United States of America, <sup>14</sup>Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR, United States of America, <sup>15</sup>Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany

- 04:19 - 05:19 **63P - Systemic therapy for KIT/PDGFR $\alpha$  wild-type GIST**  
Margaux Dupont<sup>1</sup>; M. Lamkhioued<sup>1</sup>; D. Pissaloux<sup>1</sup>; A. Meurgey<sup>1</sup>; M. Brahmi<sup>2</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, France, <sup>2</sup>Centre Léon Bérard, Lyon, CEDEX, France
- 05:19 - 06:19 **64P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Centre (NCCN) guidelines for advanced gastrointestinal stromal tumors (GIST)**  
Raul Teres Lleida; M. Aguado Sorolla; A. Romano Cardozo; F. Bosma; S. Sanchez Del Rio; A. Piedra; A. Tibau; A. Sebio Garcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 06:19 - 07:19 **65P - A phase (Ph) Ib/II study of radiotherapy (RT) in combination with surufatinib (SUR) and sintilimab (SIN) for localized high-risk limbs and trunk soft tissue sarcomas (STS): A prospective single-center trial**  
Yan Wang; S. Zhou; Y. Su; L. Xu; Z. Zhang, Fudan University Shanghai Cancer Center, Shanghai, China
- 07:19 - 08:19 **66P - Predictive nomogram for post-treatment local recurrence risk in extremity soft tissue sarcoma**  
Bhawani Pathak, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 08:19 - 09:19 **68P - Perioperative chemotherapy in localized high-risk soft tissue sarcoma of the extremities: A study based on the Latin American population**  
Haydee Williams; G. Alamilla Garcia; D. Garcia-Ortega, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- 09:19 - 10:19 **69P - Elderly patients' characteristics with soft tissue sarcoma: Experience from a Spanish reference center**  
Mercedes Cavanagh Podesta<sup>1</sup>; M. Arregui Valles<sup>2</sup>; C. López Jiménez<sup>2</sup>; R. Alvarez<sup>2</sup>, <sup>1</sup>Hospital Universitario Getafe, Madrid, Spain, <sup>2</sup>Hospital General Universitario Gregorio Marañon, Madrid, Spain
- 10:19 - 11:19 **70P - Prognosis and reasons for non-surgical treatment in >70 years old patients with soft-tissue sarcoma treated without surgery**  
Sakyo Miyagi; Y. Aoki; H. Oshiro; R. Katsuki; Y. Tome; K. Nishida, University of the Ryukyus, Okinawa, Japan
- 11:19 - 12:19 **71P - Wide resection alone for elderly patients aged >80 years old with**



### soft-tissue sarcomas

Yasunori Tome; H. Oshiro; Y. Aoki; R. Katsuki; S. Miyagi; K. Nishida, University of the Ryukyus - Graduate School of Medicine, Nishihara, Japan

- 12:19 - 13:19 **72P - Thrombosis in leiomyosarcoma: Characteristics, assessment of predictive scores and survival analysis**  
Alejandra Romano Cardozo; M. Molina Pérez; J. Navarro Keller; C. Reyes Moncayo; F. Bosma; M. Aguado Sorolla; A. Villalba; F. Pelegrín Mateo; A. Lopez Pousa; A. Sebío Garcia; R. Teres Lleida, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 13:19 - 14:19 **73P - Tumor localisation and oncological outcomes in non-uterine leiomyosarcoma of the abdomen and pelvis**  
Milan Spasojevic; A.B. Mariathasan; S. Stoldt; K. Boye; T. Holmebakk, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway
- 14:19 - 15:19 **75P - Review of the systemic treatment of leiomyosarcomas in a Spanish reference center in the last 10 years**  
S.E. Campos Ramirez<sup>1</sup>; S.E. Ruffini Egea<sup>2</sup>; M.L. Monreal Cepero<sup>2</sup>; P. Mugarza<sup>2</sup>; S. Barriendos Sanz<sup>2</sup>; P. Trincado Cobos<sup>2</sup>; F. Mocha Campillo<sup>2</sup>; N. Pascual De La Fuente<sup>2</sup>; Javier Martinez Trufero<sup>3</sup>; M.P. Felices Lobera<sup>4</sup>, <sup>1</sup>Hospital Universitario Miguel Servet, Zaragoza, Spain, <sup>2</sup>Hospital Universitario Miguel Servet, Zaragoza, Spain, <sup>3</sup>Hospital Miguel Servet, Zaragoza, Spain, <sup>4</sup>Hospital General San Jorge, Huesca, Spain
- 15:19 - 16:19 **76P - Leiomyosarcoma: Reviewing first-line options**  
Laura Fernandez<sup>1</sup>; I. Carrasco Garcia<sup>2</sup>; S. Diaz<sup>3</sup>; G. Martínez Bernal<sup>2</sup>; P. Sancho Marquez<sup>2</sup>; A.L. Moreno Vega<sup>2</sup>; M.J. Flor<sup>2</sup>, <sup>1</sup>Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, <sup>2</sup>Hospital Universitario Virgen del Rocío, Seville, Spain, <sup>3</sup>Hospital Universitario Virgen de Valme, Seville, Spain
- 16:19 - 17:19 **77P - Clinical characteristics and effects of treatment strategies for patients with orbital rhabdomyosarcoma: A retrospective study**  
M. Al-Bdour<sup>1</sup>; Ramez Odat<sup>1</sup>; N. Salameh<sup>1</sup>; L. Abu Hamdah<sup>1</sup>; J. Ibrahim<sup>1</sup>; A. Zidan<sup>2</sup>, <sup>1</sup>Jordan University of Science and Technology, IRBID, Jordan, <sup>2</sup>Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, United States of America
- 17:19 - 18:19 **79P - Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil**  
Alice Morais; M.C. Gouveia; H. Guedes; M.A.Z. De Melo; C.M. Hidalgo Filho; M. Claro; L. Stangler; R. Colombo Bonadio, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Sao Paulo, Brazil
- 18:19 - 19:19 **80P - Head and neck soft tissue sarcoma: Does margin matter?**  
Bhawani Pathak, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 19:19 - 20:19 **81P - Systemic therapy for advanced synovial sarcoma: Real-world evidence from a reference center**  
Pawel Sobczuk; I. Agnieszczak; S. Lipiec; P. Malinowski; K. Kozak; P. Teterycz; P. Rogala; T. Switaj; H. Kosela Paterczyk; S. Falkowski; P. Rutkowski, Maria Skłodowska-Curie



National Research Institute of Oncology, Warsaw, Poland

- 20:19 - 21:19 **82P - Clinicopathological characteristics analysis of malignant peripheral nerve sheath tumor in 134 cases**  
Zhuo Li, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China
- 21:19 - 22:19 **83P - Management of alveolar soft part sarcomas in LMICs: Experience from a dedicated sarcoma clinic in North India and challenges**  
S. Fernandes; S. Rastogi; Kanu Bhatia; S. Shamim; S. Gamanagatti; A. Barwad, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 22:19 - 23:19 **84P - Predictors and outcomes of recurrent retroperitoneal liposarcoma in a single center of China: New insights into its recurrence patterns**  
Huan Deng<sup>1</sup>; Y. Pan<sup>1</sup>; B. Wei<sup>2</sup>, <sup>1</sup>Peking University First Hospital, Beijing, China, <sup>2</sup>The First Affiliated Hospital of PLA General Hospital, Beijing, China
- 23:19 - 00:19 **85P - Long-term experience in the management of solitary fibrous tumors in a sarcoma reference centre**  
Roberto Diaz Beveridge; F.J. Perea Rojo; J. Esteve Gallego; C. Escriva Aranda; C. Carrasco Picazo; P. Capdevila Gaudens; D. Vidal Jiménez, Hospital Universitario La fe, VALENCIA, Spain
- 00:19 - 01:19 **86P - Advanced dermatofibrosarcoma protuberans (DFSP): Experience from a sarcoma clinic in India with 38 patients**  
Sabitha Paramasivam<sup>1</sup>; S. Rastogi<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, NEW DELHI, India, <sup>2</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 01:19 - 02:19 **87P - Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience**  
Tarek Assi<sup>1</sup>; C. Ngo<sup>2</sup>; C. Honoré<sup>1</sup>; M. Faron<sup>3</sup>; B. Verret<sup>3</sup>; R. Bahleda<sup>4</sup>; C. Henon<sup>1</sup>; C. Le Pechoux<sup>5</sup>; A. Levy<sup>6</sup>; A. Le Cesne<sup>6</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, France, <sup>2</sup>Institut Gustave Roussy, Villejuif, Cedex, France, <sup>3</sup>Institut Gustave Roussy, Villejuif, France, <sup>4</sup>Institute Gustave Roussy, Paris, CEDEX, France, <sup>5</sup>Institut Gustave Roussy, Villejuif, Cedex, CEDEX, France, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, CEDEX, France
- 02:19 - 03:19 **88P - Real-world evidence of the efficacy of ipilimumab plus nivolumab in patients with epithelioid sarcoma**  
Leonidas Mavroeidis<sup>1</sup>; L. Ferro Lopez<sup>1</sup>; J. Pozas<sup>1</sup>; P. D'Arienzo<sup>1</sup>; A. Wall<sup>1</sup>; A. Napolitano<sup>1</sup>; C. Benson<sup>1</sup>; K. Thway<sup>1</sup>; R. Jones<sup>2</sup>, <sup>1</sup>The Royal Marsden Hospital, London, United Kingdom, <sup>2</sup>The Royal Marsden Hospital, London, WA, United Kingdom
- 03:19 - 04:19 **89P - Immunotherapy response associated clinical and biological PREdictive factors in advanced SARComas: A retrospective multicenter study**  
Mina Fazel<sup>1</sup>; R. Varnier<sup>1</sup>; J.-Y. Blay<sup>2</sup>; M. Brahmi<sup>2</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, France, <sup>2</sup>Centre Léon Bérard, Lyon, CEDEX, France





- 04:19 - 05:19 **90P - Real-world data on immunotherapy in patients with soft tissue sarcoma: A study from the Hellenic Group of Sarcoma and Rare Cancers**  
Stefania Kokkali-Zervos<sup>1</sup>; A. Kyriazoglou<sup>2</sup>; A. Koumarianou<sup>3</sup>; E. Vorrias<sup>4</sup>; N. Asimakopoulou<sup>5</sup>; A. Boulouta<sup>3</sup>; E. Georgaki<sup>1</sup>; A. Papadaki<sup>6</sup>; A. Stergioula<sup>7</sup>; I. Boukovinas<sup>8</sup>, <sup>1</sup>Hippokration General Hospital, Athens, Greece, <sup>2</sup>Attikon University Hospital, Haidari, Athens, Greece, <sup>3</sup>Attikon University Hospital, Haidari, Greece, <sup>4</sup>University of Crete - School of Medicine, Heraklion, Greece, <sup>5</sup>Metropolitan General Hospital, Cholongos, Greece, <sup>6</sup>University Hospital of Ioannina, Ioannina, Greece, <sup>7</sup>IASO, Marousi, Greece, <sup>8</sup>Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece
- 05:19 - 06:19 **91P - Single-center experience on immune checkpoint inhibitors treatment in advanced and metastatic sarcoma**  
Ana Dolcan; D. Ferraro; S. Papadopoulos; G. Dei Tos; L. Wetterwald; A. Digkila, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 06:19 - 07:19 **92P - Tumour-infiltrating immune cells as a predictive factor in advanced or metastatic leiomyosarcomas: Comparison between uterine and non-uterine tumors**  
Catherine Genestie, Institut Gustave Roussy, Villejuif, Cedex, France
- 07:19 - 08:19 **93P - Evaluation of the prognostic tools in patients with localized liposarcomas, myxofibrosarcoma, undifferentiated pleomorphic sarcoma**  
Valentina Fausti<sup>1</sup>; S. Vanni<sup>1</sup>; E. Fonzi<sup>2</sup>; A. De Vita<sup>1</sup>; L. Gurrieri<sup>3</sup>; M. Riva<sup>1</sup>; F. Pieri<sup>4</sup>; N. Ranallo<sup>1</sup>; S. Calpona<sup>5</sup>; F. De Rosa<sup>1</sup>; R. Casadei<sup>6</sup>; G. Ercolani<sup>4</sup>; D. Cavaliere<sup>4</sup>; C.A. Pacilio<sup>4</sup>; D. Oboldi<sup>7</sup>; L. Ridolfi<sup>1</sup>; L. Mercatali<sup>8</sup>, <sup>1</sup>IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, Italy, <sup>2</sup>IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, <sup>3</sup>IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, (MI), Italy, <sup>4</sup>Morgagni-Pierantoni Hospital, Forlì, Italy, <sup>5</sup>IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, Forlì-Cesena, Italy, <sup>6</sup>Ospedale "Morgagni - Pierantoni" di Forlì, Forlì, Italy, <sup>7</sup>IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, Italy, <sup>8</sup>Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy
- 08:19 - 09:19 **94P - Diversity of liposarcoma expanded tumor-infiltrating lymphocytes metabolism linked to LAG3 expression**  
Cara Haymaker; J. Oliva Ramirez; Y. Lee; K. Tomczak; D.D. Truong; X. Zhou; V. Ravi; A. Conley; D. Ingram; J. Livingston; J. Ludwig; N. Somaiah, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America
- 09:19 - 10:19 **95P - The study of immune microenvironment subpopulations in soft tissue sarcomas**  
Ezozakhon Azimova<sup>1</sup>; D. Polatova<sup>2</sup>; N. Karimova<sup>1</sup>; S. Sheralieva<sup>1</sup>; N. Asamedinov<sup>1</sup>, <sup>1</sup>Tashkent State Dental Institute, Tashkent, Uzbekistan, <sup>2</sup>Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan
- 10:19 - 11:19 **96P - Immune biomarkers on tissue microarray cores support the presence of adjacent tertiary lymphoid structures in soft tissue sarcoma**



Elahe Shenasa<sup>1</sup>; S. Thornton<sup>2</sup>; D. Gao<sup>2</sup>; T. Nielsen<sup>3</sup>, <sup>1</sup>UBC - The University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>UBC - The University of British Columbia, Vancouver, Canada, <sup>3</sup>Vancouver General Hospital & HSC, British Columbia University, Vancouver, British Columbia, Canada

11:19 - 12:19 **97P - Tumor-associated macrophages: A tool for the treatment of chondrosarcoma**

Rohan Quoniou<sup>1</sup>; C. Peyrode<sup>2</sup>; E. Moreau<sup>2</sup>; E. Chautard<sup>3</sup>; F. Cachin<sup>4</sup>; C. Blavignac<sup>1</sup>; E. Miot-Noirault<sup>2</sup>, <sup>1</sup>UCA - Université Clermont Auvergne, Clermont-Ferrand, France, <sup>2</sup>IMoST - Imagerie Moléculaire et Stratégies Théranostiques - UMR 1240 Inserm / UCA, Clermont-Ferrand, France, <sup>3</sup>Centre Jean PERRIN, Clermont Ferrand, France, <sup>4</sup>Centre Jean PERRIN, Clermont-Ferrand, Cedex, France

12:19 - 13:19 **98P - Potential predictive biomarkers for response to immunotherapy in breast angiosarcoma**

Annabella Di Mauro<sup>1</sup>; G. Scognamiglio<sup>1</sup>; M. Cerrone<sup>1</sup>; R.A. Rega<sup>1</sup>; O. Clemente<sup>2</sup>; C. Mignogna<sup>1</sup>; L. Cannella<sup>2</sup>; A. Pizzolorusso<sup>2</sup>; F. Picozzi<sup>2</sup>; M. Cantile<sup>2</sup>; P. Moccia<sup>1</sup>; D. Iervolino<sup>1</sup>; A. De Chiara<sup>1</sup>; G. Ferrara<sup>1</sup>; S. Tafuto<sup>2</sup>, <sup>1</sup>Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Somma Vesuviana, Italy, <sup>2</sup>Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy

13:19 - 14:19 **99P - Postoperative adjuvant radiotherapy in primary malignant angiosarcoma of the breast patients following mastectomy or breast-conserving surgery: A retrospective study**

Ramez Odat<sup>1</sup>; M. Ali<sup>2</sup>; S. Haddadin<sup>3</sup>; B. Al Zoubi<sup>4</sup>; M. Abohalawa<sup>5</sup>; I. Ibrahim<sup>6</sup>; A. Leeper<sup>7</sup>, <sup>1</sup>Jordan University of Science and Technology, IRBID, Jordan, <sup>2</sup>South Valley University, Qena, Egypt, <sup>3</sup>Jordan University of Science and Technology, Irbid, Jordan, <sup>4</sup>Hashemite University, Al-Zarqa, Jordan, <sup>5</sup>Tanta University, Tanta, Egypt, <sup>6</sup>Fenerbahçe University, Metropol Istanbul, Turkey, <sup>7</sup>James Paget University Hospital NHS Foundation Trust, Great Yarmouth, United Kingdom

14:19 - 15:19 **100P - Impact of multiple therapeutic procedures on patients with cardiac hemangiosarcoma: A SEER-based study**

Zaid Shakhathreh<sup>1</sup>; R. Odat<sup>1</sup>; D. Nguyen<sup>2</sup>, <sup>1</sup>Jordan University of Science and Technology, IRBID, Jordan, <sup>2</sup>Massachusetts General Hospital, Corrigan Minehan Heart Center, Harvard Medical School, Boston, United States of America

15:19 - 16:19 **101P - Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center**

Carmine Valenza<sup>1</sup>; T. De Pas<sup>2</sup>; A. Gaeta<sup>3</sup>; G. Castellano<sup>1</sup>; C. Santoro<sup>1</sup>; E. Battaiotto<sup>1</sup>; M. Burroni<sup>3</sup>; G. Chiappini<sup>3</sup>; G. Vivinet<sup>4</sup>; D. Trapani<sup>1</sup>; S. Coppola<sup>5</sup>; F. Conforti<sup>2</sup>; D. Mattar<sup>3</sup>; S. Gandini<sup>3</sup>; P. Veronesi<sup>3</sup>; E. Pennacchioli<sup>3</sup>; G. Curigliano<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, Italy, <sup>2</sup>Cliniche Humanitas Gavazzeni, Bergamo, Italy, <sup>3</sup>IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, <sup>4</sup>Istituto Europeo di Oncologia IRCCS, Milan, Italy, <sup>5</sup>IEO - Istituto Europeo di Oncologia IRCCS, Milan, CEDEX, Italy

16:19 - 17:19 **102P - Redefining radiological response assessment in soft tissue sarcoma**



Iris Van Der Loo<sup>1</sup>; K. Chupetlovska<sup>1</sup>; N. Gennaro<sup>1</sup>; A. Bruining<sup>1</sup>; Z. Bodalal<sup>1</sup>; S. Reijers<sup>1</sup>; R.L. Haas<sup>1</sup>; W. Van Der Graaf<sup>1</sup>; R. Beets-Tan<sup>1</sup>; A. Imholz<sup>2</sup>; S. Trebeschi<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, <sup>2</sup>Deventer Ziekenhuis, Deventer, Netherlands

17:19 - 18:19 **103P - Using AI to break new ground in oncological drug discovery: Rapid identification of novel targets and polypharmacological compounds for effective liposarcoma treatment**

Nik Subramanian<sup>1</sup>; N. Maignan<sup>1</sup>; G. Tiew<sup>2</sup>; D. Papazian<sup>1</sup>; J. Dawe<sup>1</sup>; M. Georges<sup>1</sup>; C. Hudson Queiroz De Souza<sup>1</sup>; R. Ravinder<sup>1</sup>; S. Martin<sup>1</sup>; M. Jeitany<sup>2</sup>, <sup>1</sup>Kantify, BRUSSELS, Belgium, <sup>2</sup>NTU - Nanyang Technological University, Singapore, Singapore

18:19 - 19:19 **104P - Novel TYR-peptide potential in treatment of fibrosarcoma by targeting cancer stem cells leading to overall survival**

Karina Galoian<sup>1</sup>; C. Denny<sup>1</sup>; D. Bilbao<sup>2</sup>; N. Campos<sup>1</sup>; E. Roberts<sup>1</sup>; D. Martinez<sup>1</sup>; H.T. Temple<sup>1</sup>, <sup>1</sup>University of Miami - Miller School of Medicine, Miami, FL, United States of America, <sup>2</sup>University of Miami - Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States of America

19:19 - 20:19 **105P - LX-101, a novel, clinical stage, payload-bearing, IGF-1R targeted therapy, has potent preclinical anti-tumor activity against sarcomas and other IGF-related cancers**

Matthew Hoberman, Lirum Therapeutics, Inc., New York, United States of America

20:19 - 21:19 **106P - Pharmacogenetic profiling in osteosarcoma to predict response and toxicity to neoadjuvant MAP: A study from the GEIS 33 protocol**

Ana Sebio Garcia<sup>1</sup>; J. Martin-Broto<sup>2</sup>; F.J. Bautista Sirvent<sup>3</sup>; J. Martinez-Garcia<sup>4</sup>; J. Martinez Trufero<sup>5</sup>; Y. Vidal Insua<sup>6</sup>; A. Echevarria Barona<sup>7</sup>; R. Diaz Beveridge<sup>8</sup>; C.M. Valverde Morales<sup>9</sup>; P. Luna Fra<sup>10</sup>; M.A. Vaz Salgado<sup>11</sup>; P.M. Blay Albors<sup>12</sup>; R. Alvarez<sup>13</sup>; J. Salazar<sup>14</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>2</sup>Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, <sup>3</sup>Hospital Universitario Infantil Nino Jesus, Madrid, ES, Spain, <sup>4</sup>Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain, <sup>5</sup>Hospital Miguel Servet, Zaragoza, Spain, <sup>6</sup>Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, <sup>7</sup>Hospital Universitario Cruces, Barakaldo, Spain, <sup>8</sup>Hospital Universitario La fe, Valencia, Spain, <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>10</sup>Hospital Universitario Son Espases, Palma de Mallorca, Spain, <sup>11</sup>Hospital Universitario Ramon y Cajal, Madrid, Spain, <sup>12</sup>Hospital Universitario Central de Asturias, Oviedo, Spain, <sup>13</sup>Hospital General Universitario Gregorio Maranon, Madrid, Spain, <sup>14</sup>Institut Recerca Biomedica Sant Pau, Barcelona, Spain

21:19 - 22:19 **107P - Eradication of osteosarcoma cells with methioninase combined with ethionine is associated with down-regulation of beta catenin/cyclin-D1**

Yusuke Aoki<sup>1</sup>; Y. Tome<sup>1</sup>; H. Oshiro<sup>1</sup>; R. Katsuki<sup>1</sup>; S. Miyagi<sup>1</sup>; K. Nishida<sup>1</sup>; R. Hoffman<sup>2</sup>, <sup>1</sup>University of the Ryukyus, Okinawa, Japan, <sup>2</sup>University of California San Diego - UCSD, La Jolla, CA, United States of America

22:19 - 23:19 **108P - Safety and efficacy of fruquintinib (FRU)-based therapy in patients (Pts)**



**with advanced or metastatic osteosarcoma: A real-world study**

Chenliang Zhou; Z. Shen; S. Zheng, Shanghai Sixth People's Hospital, Jiaotong University, Shanghai, China

23:19 - 00:19

**109P - Combined bone recycling with liquid nitrogen and megaprosthesis in osteosarcoma surgery: A retrospective case series review**

Sang Nguyen Tran Quang, Vinmec International Hospital, Hanoi, Viet Nam

00:19 - 01:19

**110P - The relationship between tumor necrosis, histopathology type, and preoperative chemotherapy regimens in patients with osteosarcoma**

Khanh Van Nguyen<sup>1</sup>; H. Tran<sup>2</sup>; T. Tran Duc<sup>3</sup>; Q. Dang<sup>3</sup>; T. Dung<sup>3</sup>; S. Nguyen Tran Quang<sup>2</sup>, <sup>1</sup>Vinmec Healthcare System, Hanoi, Viet Nam, <sup>2</sup>Vinmec International Hospital, Hanoi, Viet Nam, <sup>3</sup>VinUniversity, Hanoi, Viet Nam

01:19 - 02:19

**111P - Oncologic outcomes of the pelvic bone tumors**

Abbos Nurjabov<sup>1</sup>; N. Kamalovich<sup>2</sup>; N. Asamedinov<sup>1</sup>; D. Polatova<sup>3</sup>; O. Abdusattorov<sup>1</sup>; D. Rasulbek Rakhimberdiyevich<sup>4</sup>; K. Abdikarimov<sup>3</sup>, <sup>1</sup>Tashkent State Dental Institute, Tashkent, Uzbekistan, <sup>2</sup>Tashkent Medical Academy, Tashkent, Uzbekistan, <sup>3</sup>Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan, <sup>4</sup>Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology, Urgench, Uzbekistan

02:19 - 03:19

**112P - Real-world data of OGS-12 protocol on non-metastatic extremity osteosarcoma: A multicentric study**

Megha K<sup>1</sup>; P. Kumar<sup>1</sup>; M. Kapoor<sup>2</sup>; A. Sehrawat<sup>3</sup>; D. Sundriyal<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, India, <sup>2</sup>AIIMS - All India Institute of Medical Science - Rishikesh, Rishikesh, India, <sup>3</sup>All India Institute of Medical Sciences, Rishikesh, India

03:19 - 04:19

**113P - Real-world data from patients with osteosarcoma treated in 4 medical centers in Greece: Ninety percent or greater tumor necrosis is associated with disease-free survival**

M. Moutafi<sup>1</sup>; Anastasios Kyriazoglou<sup>2</sup>; I. Kotsantis<sup>3</sup>; S. Kokkali-Zervos<sup>4</sup>; P. Antonopoulou<sup>1</sup>; G. Ardavanis<sup>5</sup>; E. Magkou<sup>5</sup>; E. Georgaki<sup>4</sup>; M. Anastasiou<sup>1</sup>; A. Pantazopoulos<sup>3</sup>; A. Boulouta<sup>1</sup>; M. Kirkasiadou<sup>3</sup>; N. Gavrielatou<sup>1</sup>; P. Economopoulou<sup>3</sup>; A. Ardavanis<sup>5</sup>; I. Boukovinas<sup>6</sup>; A. Psyrris<sup>3</sup>, <sup>1</sup>Attikon University Hospital, Athens, Greece, <sup>2</sup>Attikon University Hospital, Haidari, Athens, Greece, <sup>3</sup>Attikon University Hospital, Haidari, Greece, <sup>4</sup>Hippokraton General Hospital, Athens, Greece, <sup>5</sup>Agios Savvas - Anticancer Hospital, Athens, Greece, <sup>6</sup>Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece

04:19 - 05:19

**114P - Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: A single-center experience of 11 years in Tianjin, China**

Chao Zhang; H. Wu; J. Zhang, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

05:19 - 06:19

**115P - Outcomes of the first 11 cases of total femur replacement due to osteosarcoma in Vietnam: What lessons do we learn?**



Thanh Tran Duc; S. Nguyen Tran; Q. Dang Minh; K. Van Nguyen; H. Le; T. Dung, Vinmec Healthcare System, Hanoi, Viet Nam

- 06:19 - 07:19 **116P - Role of extracorporeal irradiation in primary malignant bone tumors**  
Soel Ahmed<sup>1</sup>; S.K. Das Majumdar<sup>2</sup>; S. Barik<sup>3</sup>; D. Das<sup>4</sup>; P. Mukherjee<sup>1</sup>; D.K. Parida<sup>1</sup>,  
1AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, India,  
2AIIMS-All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, Odisha,  
India, 3All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, India, 4All  
India Institute of Medical Sciences, Bhubaneswar, India
- 07:19 - 08:19 **117P - Prognostic factors and outcomes in neoadjuvant treatment in  
osteosarcoma: A single national center experience in Peru**  
Jessica Meza<sup>1</sup>; J. Haro Varas<sup>1</sup>; V. Paitan Amaro<sup>1</sup>; J. Medina<sup>1</sup>; J. Sanchez<sup>1</sup>; M. Alcalde<sup>1</sup>; C.  
Pacheco<sup>1</sup>; L. Zeta<sup>2</sup>; V. Castro Oliden<sup>1</sup>, 1INEN - Instituto Nacional de Enfermedades  
Neoplasicas, Lima, Peru, 2Universidad Peruana Cayetano Heredia-North Campus, Lima,  
Peru
- 08:19 - 09:19 **118P - Influence of radiotherapy dose on pattern of local recurrence for clival  
and spinal chordoma treated with proton/photon radiotherapy**  
Hanis Hanafi; J. Tsui; F. Cury; C. Freeman, McGill University Health Centre, Montreal,  
Canada
- 09:19 - 10:19 **119P - Insight into early response of sacral chordomas (SC) to high-dose proton  
therapy (HDPT): First results of CHIPT study**  
Vesna Miladinovic<sup>1</sup>; A. Krol<sup>2</sup>; A. Navas<sup>1</sup>; J. Bloem<sup>1</sup>, 1LUMC-Leiden University Medical  
Center, Leiden, Netherlands, 2HollandPTC, Delft, Netherlands
- 10:19 - 11:19 **120P - Discovery of prognostic biomarkers in Ewing sarcoma**  
Anastasios Kyriazoglou<sup>1</sup>; M. Moutafi<sup>2</sup>; E. Zografos<sup>3</sup>; V. Konteles<sup>4</sup>; G. Sofianidis<sup>5</sup>; L.  
Mahaira<sup>4</sup>; A. Papakosta<sup>4</sup>; N. Tourkantoni<sup>6</sup>; A. Patereli<sup>6</sup>; K. Stefanaki<sup>6</sup>; V. Tzotzola<sup>6</sup>; M.  
Baka<sup>7</sup>; S. Polychronopoulou<sup>6</sup>; E. Dimitriadis<sup>4</sup>; A. Kattamis<sup>3</sup>, 1Attikon University Hospital,  
Haidari, Athens, Greece, 2Attikon University Hospital, Athens, Greece, 3National and  
Kapodistrian University of Athens, Athens, Greece, 4Agios Savvas - Anticancer Hospital,  
Athens, Greece, 5Aristotle University of Thessaloniki, Thessaloniki, Greece, 6Agia Sofia  
Hospital, Athens, Greece, 7Children's Hospital of Athens Aglaia Kyriakou, Athens, Greece
- 11:19 - 12:19 **121P - Radiological staging with FDG-PET vs WB-MRI in Ewing sarcoma in the  
era of precision treatment**  
Adit Bassi<sup>1</sup>; A. Mitchell<sup>2</sup>; J. Gains<sup>3</sup>; S. Wan<sup>3</sup>; S. Singh<sup>3</sup>; P.S. Lim<sup>4</sup>, 1UCL - University  
College London, London, United Kingdom, 2UCH - University College Hospital, London,  
United Kingdom, 3UCLH - University College London Hospitals NHS Foundation Trust,  
London, United Kingdom, 4University College London Hospital - University College  
London Hospitals NHS Foundation Trust, London, United Kingdom
- 12:19 - 13:19 **122P - Ewing sarcoma treatment in Tunisian population: VDC/IE versus VIDE**  
Hend Mrad<sup>1</sup>; N. Kooli<sup>2</sup>; H. Ben Mansour<sup>1</sup>; Z. Ghodhbani<sup>3</sup>; Y. Zenzri<sup>4</sup>; K. Meddeb<sup>1</sup>; N.  
Chraiet<sup>1</sup>; A. Mezlini<sup>1</sup>, 1ISA - Institut Salah Azaiez, Tunis, Tunisia, 2Salah Azaiez Institute,



tunis, Tunisia, <sup>3</sup>Salah Azaiez, Tunis, Tunisia, <sup>4</sup>Institut Salah Azaiz, Tunis, Tunisia

- 13:19 - 14:19 **123P - A nomogram may predict survival of adolescent and young adult (AYA) patients with locally advanced Ewing sarcoma**  
Piotr Rutkowski<sup>1</sup>; P. Jagodzinska-Mucha<sup>1</sup>; S. Kopec<sup>1</sup>; M. Rosinska<sup>1</sup>; P. Sobczuk<sup>2</sup>; K. Kozak<sup>1</sup>; P. Teterycz<sup>1</sup>; I. Lugowska<sup>1</sup>; K. Bilska<sup>3</sup>; A. Raciborska<sup>4</sup>, <sup>1</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>2</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>3</sup>Institute of Mother and Child, Warsaw, Poland, <sup>4</sup>Centrum Medicover, Warsaw, Poland
- 14:19 - 15:19 **124P - Ewing's sarcoma in adolescents and adults: 12-year experience from a reference center in Peru**  
Iris Otoya E.; L. Chavez Jimenez; C. Calle; J. Haro Varas; V. Paitan Amaro; M.J. Calderon Anticona; C. Pacheco; V. Castro Oliden, INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
- 15:19 - 16:19 **125P - Trabectedin as second line: Data of a high-volume center around the last 5 years**  
Sebastian Diaz<sup>1</sup>; G. Martínez Bernal<sup>2</sup>; L. Fernandez<sup>3</sup>; I. Carrasco Garcia<sup>2</sup>; A.L. Moreno Vega<sup>2</sup>; P. Sancho Marquez<sup>2</sup>; M.J. Flor<sup>2</sup>, <sup>1</sup>Hospital Universitario Virgen de Valme, Seville, Spain, <sup>2</sup>Hospital Universitario Virgen del Rocio, Seville, Spain, <sup>3</sup>Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
- 16:19 - 17:19 **126P - Quality of life (QoL) as endpoint in mesenchymal tumor-related randomized controlled trials (RCTs)**  
Flavia Paternostro; D. Romandini; S. Orlando; M. Silletta; B. Vincenzi; A. Mazzocca, Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Rome, Italy
- 17:19 - 18:19 **127P - Laparoscopic approach as a safe method for treatment of retroperitoneal sarcomas**  
Veronika Patsko; K. Cherchenko; Y. Ostapenko; A. Lukashenko, National Cancer Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
- 18:19 - 19:19 **128P - Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection**  
Quang Dang; S. Nguyen Tran Quang; T. Tran Duc; T. Dung; C. Tran Van; H. Le; H. Tran; K. Van Nguyen, Vinmec Healthcare System, Hanoi, Viet Nam
- 19:19 - 20:19 **129P - Surgical site infection rates in bone cancer surgery after pre-operative methicillin-resistant Staphylococcus aureus screening**  
Ly Nguyen; T. Dung; L. Phan; H. Duong; T. Tran Duc; T. Nguyen; H. Le; Q. Dang Minh, Vinmec International Hospital, Hanoi, Viet Nam
- 20:19 - 21:19 **130P - Efficacy of plasma D-dimer screening for preoperative thrombosis and prevention of postoperative symptomatic pulmonary embolism in sarcoma patients: A retrospective observation study**  
Hiroya Kondo; E. Kobayashi; S. Fukushima; S. Osaki; K. Ogura; S. Iwata; A. Kawai, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, Japan



- 21:19 - 22:19 **131P - Proximal humerus reconstructions for tumors: A comprehensive study from a single institution**  
Thanh Tran Duc; S. Nguyen Tran; Q. Dang Minh; H. Le; K. Van Nguyen; T. Dung, Vinmec Healthcare System, Hanoi, Viet Nam
- 22:19 - 23:19 **132P - Clinical utility of whole genome sequencing (WGS) for the identification of actionable genetic alterations in sarcoma patients**  
Georgina Wood; S. Abdulla; M. Ahmed; R. Windsor, UCLH - University College London Hospitals NHS Foundation Trust, London, United Kingdom
- 23:19 - 00:19 **133P - Molecular profile and actionability of sarcomas with next-generation sequencing: Insights from a single institution in Brazil**  
Miguel Zugman<sup>1</sup>; M. Fernandes<sup>2</sup>; L. De Lima<sup>2</sup>; M. Teixeira<sup>1</sup>; T. Xavier<sup>2</sup>; I. Dias<sup>2</sup>; U. Junior<sup>2</sup>; K. Pelegrino<sup>2</sup>; L. Côrtes<sup>2</sup>; D. Silva<sup>1</sup>; E. Silva<sup>2</sup>; J. Beal<sup>1</sup>; P. Serrano Uson Junior<sup>1</sup>; P. Vidal Campregher<sup>2</sup>; F. Moura<sup>3</sup>; R. Zon Filippi<sup>2</sup>; R. Jesus-Garcia<sup>1</sup>; R. Carmagnani Pestana<sup>1</sup>, <sup>1</sup>Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, Sao Paulo, Brazil, <sup>2</sup>Hospital Israelita Albert Einstein, São Paulo, Brazil, <sup>3</sup>Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, Sao Paulo, SP, Brazil
- 00:19 - 01:19 **134P - Characterizing sarcoma molecular landscape by nanopore adaptive sampling sequencing**  
Aviad Zick<sup>1</sup>; M. Maoz<sup>1</sup>; B. Ben-Kuzari<sup>1</sup>; I. Lavon<sup>2</sup>; A. Iluz<sup>2</sup>; O. Or<sup>3</sup>; N. Olshinka<sup>3</sup>; J.A. Demma<sup>3</sup>; M. Adileh<sup>3</sup>; M. Wygoda<sup>3</sup>; P. Blumenfeld<sup>3</sup>; M. Gliner-Ron<sup>3</sup>; Y. Azraq<sup>3</sup>; J. Diment<sup>3</sup>; J. Moss<sup>1</sup>; T. Peretz-Yablonski<sup>1</sup>; G. Vainer<sup>3</sup>; A. Darwish<sup>4</sup>; S. Isaac<sup>4</sup>; A. Eden<sup>4</sup>, <sup>1</sup>Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, <sup>2</sup>Hadassah University Hospital - Ein Kerem, Jerusalem, Israel, <sup>3</sup>Hadassah-Hebrew University Medical Center, Jerusalem, Israel, <sup>4</sup>The Hebrew University of Jerusalem, Jerusalem, Israel
- 01:19 - 02:19 **135P - Influence of next generation sequencing on sarcomas management in the real-world setting in Oman: Retrospective single institution analysis**  
Boris Itkin<sup>1</sup>; H. Al-Sayegh<sup>2</sup>; P. Deshpande<sup>2</sup>; D. Abdou<sup>3</sup>; A. Pullanhi<sup>2</sup>; Z. Sawaya<sup>4</sup>; S. Al Zadjali<sup>2</sup>; I. Al Haddabi<sup>2</sup>, <sup>1</sup>SQCCRC - Sultan Qaboos Comprehensive Cancer Care and Research Centre, Seeb, Oman, <sup>2</sup>SQCCRC - Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman, <sup>3</sup>Sultan Qaboos Comprehensive Cancer Care and Research Center, Seeb, Oman, <sup>4</sup>Universite Saint Joseph de Beirut, Beirut, Lebanon
- 02:19 - 03:19 **136P - Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer**  
Daniel Orbach<sup>1</sup>; C.M. Zwaan<sup>2</sup>; C.M. Albert<sup>3</sup>; N. Federman<sup>4</sup>; A. Pappo<sup>5</sup>; V. Bernard-Gauthier<sup>6</sup>; N. Neu<sup>7</sup>; E. De La Cuesta<sup>8</sup>; T. Laetsch<sup>9</sup>; Y. Zhang<sup>10</sup>, <sup>1</sup>Institut Curie, Paris, France, <sup>2</sup>Prinses Máxima Centrum, Utrecht, Netherlands, <sup>3</sup>Seattle Children's Hospital and University of Washington School of Medicine, Seattle, United States of America, <sup>4</sup>David Geffen School of Medicine, University of California, Los Angeles, United States of America, <sup>5</sup>St. Jude Children's Research Hospital, Memphis, United States of America, <sup>6</sup>Bayer Pharmaceuticals, Inc., Toronto, Canada, <sup>7</sup>Chrestos Concept GmbH & Co. KG, Essen, Germany, <sup>8</sup>Bayer Pharmaceuticals, Inc., Toronto, AB, Canada, <sup>9</sup>Children's Hospital



of Philadelphia, University of Pennsylvania, Philadelphia, United States of America, <sup>10</sup>Sun Yat-sen University Cancer Center, Guangzhou, China

- 03:19 - 04:19 **138P - Clinicopathological characteristics and outcomes of adolescent and young adult sarcoma patients seen at a tertiary cancer center in the Philippines**  
Carl Lawrence Arenos; S. Estreller; J.P. Torres; F. Gracieux Jr.; A.P. Alcasabas, University of the Philippines - Philippine General Hospital, Manila, Philippines
- 04:19 - 05:19 **139TiP - Neoadjuvant MAP in patients aged 24-40 years with osteosarcoma under the coverage of hemodialysis: Ongoing trial**  
Anastasia Tararykova; A. Konev; B. Bokhyan; A. Valiev; E. Gromova, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 05:19 - 06:19 **140TiP - Brightline-4: A phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma**  
Scott Schuetze<sup>1</sup>; G. Jayadeva<sup>2</sup>; M. Santoro<sup>2</sup>, <sup>1</sup>University of Michigan Rogel Cancer Center, Ann Arbor, MI, United States of America, <sup>2</sup>Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America
- 06:19 - 07:19 **141TiP - Cemiplimab treatment in patients with locally advanced and metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial in progress**  
S. Van Ravensteijn<sup>1</sup>; J. De Haan<sup>2</sup>; H. Gelderblom<sup>3</sup>; Y. Versleijen-Jonkers<sup>4</sup>; F. Speetjens<sup>5</sup>; S. Kaal<sup>4</sup>; M. Smits<sup>6</sup>; C. Van Herpen<sup>7</sup>; Ingrid Desar<sup>4</sup>, <sup>1</sup>Radboud University Medical Center, Nijmegen, Berghem, Netherlands, <sup>2</sup>UMCG - University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands, <sup>4</sup>Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, <sup>5</sup>LUMC - Universitair Medisch Centrum, Leiden, Netherlands, <sup>6</sup>Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, <sup>7</sup>Radboud University Medical Center, Nijmegen, Netherlands
- 07:19 - 08:19 **142TiP - SARC-Digital: An obServational, rANdomized, pROspeCtive study of the impact of digital health interventions on symptom and side-effect management in patients with metastatic sarcoma**  
Stefania Kokkali-Zervos<sup>1</sup>; J. Durán Moreno<sup>2</sup>; A. Kyriazoglou<sup>3</sup>; V. Georgoulis<sup>4</sup>; I. Athanasiadis<sup>5</sup>; A. Koumarianou<sup>6</sup>; N. Tsoukalas<sup>7</sup>; V. Ramfidis<sup>8</sup>; A. Stergioula<sup>9</sup>; P. Kosmidis<sup>10</sup>; D. Valoukas<sup>11</sup>; D. Tzanninis<sup>12</sup>; G. Varvaris<sup>13</sup>; P. Baxevanos<sup>13</sup>; T. Kosmidis<sup>13</sup>; V. Schoina<sup>14</sup>; I. Boukovinas<sup>15</sup>, <sup>1</sup>Hippokration General Hospital, Athens, Greece, <sup>2</sup>Private Practice, Athens, Greece, <sup>3</sup>Attikon University Hospital, Haidari, Athens, Greece, <sup>4</sup>Metropolitan General Hospital, Cholargos, Greece, <sup>5</sup>Mitera Hospital, Marousi, Greece, <sup>6</sup>Attikon University Hospital, Haidari, Greece, <sup>7</sup>401 General Military Hospital of Athens, Athens, Greece, <sup>8</sup>251 Hellenic Airforce General Hospital, Athens, Greece, <sup>9</sup>IASO General Hospital, Cholargos/Holargos, Greece, <sup>10</sup>Hygeia Hospital, Marousi, Greece, <sup>11</sup>Private Practice - Dr. Dimitrios Valoukas, Thessaloniki, Central Macedonia, Greece, <sup>12</sup>Athens Medical Center SA Maroussi, Marousi, Greece, <sup>13</sup>Care Across Ltd, London, United Kingdom, <sup>14</sup>Hellenic Group of Sarcoma and Rare Cancers, Athens, Greece, <sup>15</sup>Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, Greece





08:19 - 08:19 **Skin cancers and Melanomas**

08:19 - 09:19 **143P - Molecular profiling and treatment-related outcomes with chemo-immunotherapy in patients with mucosal melanoma: A 10-year single-centre retrospective study**

Prashant Jambunathan<sup>1</sup>; A. Singh<sup>1</sup>; Z. Thomas<sup>1</sup>; D.B. Thumaty<sup>2</sup>; J. Georgy<sup>1</sup>; A. John<sup>3</sup>; P.K. Marimuthu<sup>3</sup>; H. Kovilapu<sup>1</sup>; M. Thomas<sup>3</sup>; D. Masih<sup>1</sup>; B. Roopavathana<sup>1</sup>; B.K. Sasidharan<sup>2</sup>,  
<sup>1</sup>CMC - Christian Medical College Hospital, Vellore, India, <sup>2</sup>CMC - Christian Medical College Hospital, Vellore, Tamil Nadu, India, <sup>3</sup>CMC - Christian Medical College Hospital Vellore, Vellore, India

09:19 - 10:19 **144P - Influence of tumor-infiltrating T-cells' characteristics on the survival of patients with primary choroid melanoma**

Iryna Zherka<sup>1</sup>; O. Gulenko<sup>2</sup>; K. Ruksha<sup>2</sup>; D. Davidov<sup>2</sup>; L. Naumenko<sup>2</sup>; A. Portyanko<sup>1</sup>,  
<sup>1</sup>State Institution N. N. Alexandrov National Cancer Centre of Belarus, Lesnoy - Minsk District, Belarus, <sup>2</sup>N.N. Alexandrov National Cancer Center of Belarus, Lesnoy - Minsk District, Belarus

10:19 - 10:19 **Thoracic cancers**

10:19 - 11:19 **145P - Real-world evidence on thymic epithelial tumours (TETs): A decade of surgical experience and recurrence outcomes**

E. Josephides<sup>1</sup>; A. Patel<sup>2</sup>; G. Lucchese<sup>2</sup>; C. Morton<sup>3</sup>; Spyridon Gennatas<sup>3</sup>; J. Spicer<sup>4</sup>; A. Georgiou<sup>3</sup>; S. Ghosh<sup>3</sup>; D. Smith<sup>1</sup>; S. Ahmad<sup>1</sup>; M. Skwarski<sup>1</sup>; H. Rush<sup>5</sup>; R. Di Marco Barros<sup>3</sup>; M. Van Hemelrijck<sup>6</sup>; E. Karapanagiotou<sup>3</sup>; A. Bille<sup>2</sup>, <sup>1</sup>Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, <sup>2</sup>Guys and St Thomas NHS Trust, London, United Kingdom, <sup>3</sup>Guy's and St. Thomas' Hospital NHS Trust, London, United Kingdom, <sup>4</sup>KCL - King's College London, London, United Kingdom, <sup>5</sup>University College London, London, United Kingdom, <sup>6</sup>King's College London - KCL, London, United Kingdom

11:19 - 11:19 **General interest**

11:19 - 12:19 **148P - The impact of desmoid tumors on patients' quality of life: Desmoid Tumor Research Foundation Natural History Study**

K. Mercier<sup>1</sup>; L. Hernandez<sup>2</sup>; Amanda Lucas<sup>2</sup>; T. Bell<sup>3</sup>; B. Tumminello<sup>4</sup>; S. Zhou<sup>3</sup>, <sup>1</sup>Duke Cancer Center - Duke University Medical Center, Durham, United States of America, <sup>2</sup>Desmoid Tumor Research Foundation, Woodcliff Lake, NJ, United States of America, <sup>3</sup>SpringWorks Therapeutics Inc, Stamford, United States of America, <sup>4</sup>SpringWorks Therapeutics, Inc, Stamford, United States of America

12:19 - 13:19 **149P - Treatment landscape for desmoid tumors: Desmoid Tumor Research Foundation Natural History Study**

K. Mercier<sup>1</sup>; L. Hernandez<sup>2</sup>; Amanda Lucas<sup>2</sup>; T. Bell<sup>3</sup>; A. Oton<sup>3</sup>; S. Zhou<sup>3</sup>, <sup>1</sup>Duke Cancer



Center - Duke University Medical Center, Durham, United States of America, <sup>2</sup>Desmoid Tumor Research Foundation, Woodcliff Lake, NJ, United States of America, <sup>3</sup>SpringWorks Therapeutics, Inc, Stamford, United States of America

- 13:19 - 14:19 **150P - Sorafenib is an active and cost-effective treatment modality in patients with symptomatic desmoid tumors**  
Diego Soriano Polo<sup>1</sup>; R. Diaz Beveridge<sup>2</sup>; J. Esteve Gallego<sup>2</sup>; C. Escriva Aranda<sup>2</sup>; C. Carrasco Picazo<sup>2</sup>; P. Capdevila Gaudens<sup>2</sup>; D. Vidal Jiménez<sup>2</sup>, <sup>1</sup>Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain, <sup>2</sup>Hospital Universitario La fe, VALENCIA, Spain
- 14:19 - 15:19 **151P - Mesothelioma tunica vaginalis testis: Characteristics and treatment outcome of a consecutive cohort**  
Jens Sørensen; E. Santoni-Rugiu, Rigshospitalet, Copenhagen, Denmark
- 15:19 - 16:19 **152P - Exploring the tissue specificity of recurrent rare cancer fusion oncogenes**  
Arshia Kaur; A. Frederick; F. Keller; R. Magesh; E. Watson, UMass Chan Medical School, Worcester, United States of America
- 16:19 - 17:19 **153P - The preoperative treatment of patients with giant cell tumors of limb bones by denosumab therapy**  
Nasirov Kamalovich<sup>1</sup>; D. Polatova<sup>2</sup>; K. Abdikarimov<sup>3</sup>; D. Rasulbek Rakhimberdiyevich<sup>3</sup>; N. Asamedinov<sup>2</sup>; A. Nurjabov<sup>2</sup>; O. Abdusattorov<sup>2</sup>; E. Azimova<sup>2</sup>; I. Abdulazizovna<sup>2</sup>, <sup>1</sup>Tashkent Medical Academy, Tashkent, Uzbekistan, <sup>2</sup>Tashkent State Dental Institute, Tashkent, Uzbekistan, <sup>3</sup>Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan
- 17:19 - 18:19 **154P - Impact of denosumab as neoadjuvant treatment for giant cell bone tumors: Insights from Peru**  
L. Chavez Jimenez; I. Otoya F.; Cindy Calle; J. Haro Varas; A.D. Leonardo Carbajal; V. Paitan Amaro; V. Velezmoro; M. Flores; R. Pareja; M.J. Calderon Anticona; C. Pacheco; V. Castro Oliden, INEN - Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
- 18:19 - 19:19 **155P - Systemic bevacizumab in pediatric patients with aggressive recurrent respiratory papillomatosis**  
Zengjun Liu<sup>1</sup>; J. Xu<sup>1</sup>; M. Liu<sup>1</sup>; D. Zhu<sup>1</sup>; Y. Xiao<sup>2</sup>, <sup>1</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, <sup>2</sup>Beijing Tongren Hospital, Beijing, China
- 19:19 - 20:19 **156P - Next-generation sequencing failure due to sample quality issues in rare tumors: Retrospective single-institution analysis**  
Boris Itkin<sup>1</sup>; D. Abdou<sup>2</sup>; P. Deshpande<sup>3</sup>; A. Pullanhi<sup>3</sup>; Z. Sawaya<sup>2</sup>; S. Al Zadjali<sup>3</sup>; I. Al Haddabi<sup>3</sup>; H. Al-Sayegh<sup>3</sup>, <sup>1</sup>SQCCCRC - Sultan Qaboos Comprehensive Cancer Care and Research Centre, Seeb, Oman, <sup>2</sup>Sultan Qaboos Comprehensive Cancer Care and Research Center, Seeb, Oman, <sup>3</sup>SQCCCRC - Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman



20:19 - 21:19 **157P - Clinicopathological features of first primary myeloid sarcoma and the risk of multiple primary malignancies**

Nahla Ali<sup>1</sup>; A. Ellaithy<sup>2</sup>, <sup>1</sup>Alexandria Faculty of Medicine, Alexandria, Egypt, <sup>2</sup>Suez Canal University Hospital, Ismailia, Egypt

**12:15 - 13:00 Type: Young Oncologists session** **Hall B3**  
**Title: YO Vesalius Talk**

Moderation: Pawel Sobczuk, Poland; Christoph Oing, United Kingdom

12:15 - 13:00 **Everywhere, everything, all at once: Managing work-life overload**

Dario Callegaro<sup>1</sup>; Sarah Watson<sup>2</sup>; William D. Tap<sup>3</sup>; Lisa Licitra<sup>1</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, <sup>2</sup>Institut Curie, Paris, France, <sup>3</sup>MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

**13:00 - 14:00 Type: Abstract session** **Hall A**  
**Title: Mini Oral session**

Moderation: George Demetri, United States of America; Marco Fiore, Italy

13:00 - 13:05 **57MO - Impact of nirogacestat (niro) on patient-reported outcomes (PROs) in adults with desmoid tumor with a best overall response (BOR) of stable disease (SD): Post hoc analysis from the DeFi study**

Silvia Stacchiotti<sup>1</sup>; S. Chawla<sup>2</sup>; R. Chugh<sup>3</sup>; G. D'Amato<sup>4</sup>; M. Gounder<sup>5</sup>; R. Ratan<sup>6</sup>; W. Van Der Graaf<sup>7</sup>; V. Amoruccio<sup>8</sup>; T. Bell<sup>8</sup>; S. Cho<sup>8</sup>; P. Schöffski<sup>9</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, <sup>2</sup>Sarcoma Oncology Research Center, Santa Monica, CA, United States of America, <sup>3</sup>University of Michigan, Ann Arbor, United States of America, <sup>4</sup>University of Miami, Miami, United States of America, <sup>5</sup>Memorial Sloan Kettering Evelyn H. Lauder Breast Center & Weill Cornell Medical College, New York, NY, United States of America, <sup>6</sup>The University of Texas, Houston, United States of America, <sup>7</sup>Netherlands Cancer Institute, Amsterdam, Netherlands, <sup>8</sup>SpringWorks Therapeutics, Inc., Stamford, United States of America, <sup>9</sup>University Hospitals Leuven & KU Leuven, Leuven Cancer Institute, Leuven, Belgium

13:05 - 13:10 **58MO - Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment**

Silvia Stacchiotti<sup>1</sup>; A.J. Wagner<sup>2</sup>; I. Carrasco Garcia<sup>3</sup>; M. Cesari<sup>4</sup>; M. Gordon<sup>5</sup>; C.-C. Lin<sup>6</sup>; Z. Papai<sup>7</sup>; C. Ryan<sup>8</sup>; W.D. Tap<sup>9</sup>; J. Trent<sup>10</sup>; H. Gelderblom<sup>11</sup>; P. Grimison<sup>12</sup>; A. Lopez Pousa<sup>13</sup>; B.A. Van Tine<sup>14</sup>; M. Rubinacci<sup>15</sup>; K. Tecson<sup>15</sup>; M. Wooddell<sup>15</sup>; J. Desai<sup>16</sup>, <sup>1</sup>Istituto Nazionale dei Tumori, Milan, Italy, <sup>2</sup>Dana Farber Cancer Institute, Boston, MA, United States of America, <sup>3</sup>Virgen del Rocio University Hospital, Seville, Spain, <sup>4</sup>IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, <sup>5</sup>HonorHealth Research Institute, Scottsdale, AZ, United States of America, <sup>6</sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>7</sup>Semmelweis University, Budapest, Hungary, <sup>8</sup>Oregon Health & Science University, Portland, OR, United States of America, <sup>9</sup>and Weill Cornell Medical College, New York, NY, United States of America, <sup>10</sup>Sylvester Comprehensive Cancer Center, Miami, FL, United States of America, <sup>11</sup>Leiden University Medical Center, Leiden, Netherlands, <sup>12</sup>Chris O'Brien Lifehouse, Sydney, NSW, Australia, <sup>13</sup>Hospital de la Santa Cruz i Sant Pau, Barcelona, Spain, <sup>14</sup>and Washington University School of Medicine in St. Louis, St. Louis, MO, United States of America, <sup>15</sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, United



States of America, <sup>16</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

- 13:10 - 13:15 **59MO - COTESARC 2013; A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts**
- Armelle Dufresne<sup>1</sup>; M. Brahmi<sup>2</sup>; C. Cropet<sup>3</sup>; R. Bahleda<sup>4</sup>; S. Watson<sup>5</sup>; P. Pautier<sup>6</sup>; I. Ray-Coquard<sup>2</sup>; I. Aerts<sup>7</sup>; F. Duffaud<sup>8</sup>; A.-S. Defachelles<sup>9</sup>; B. Verret<sup>10</sup>; G. Fournier Garin<sup>3</sup>; C. Guichard<sup>3</sup>; M. Bernardin<sup>3</sup>; D. Perol<sup>2</sup>; J.-Y. Blay<sup>2</sup>; N. Corradini<sup>11</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, CEDEX 3, France, <sup>2</sup>Centre Léon Bérard, Lyon, CEDEX, France, <sup>3</sup>Centre Léon Bérard, Lyon, France, <sup>4</sup>Institute Gustave Roussy, Paris, CEDEX, France, <sup>5</sup>Institut Curie, Paris, France, <sup>6</sup>Institut Gustave Roussy, Villejuif, Cedex, CEDEX, France, <sup>7</sup>Institut Curie, PARIS, France, <sup>8</sup>CHU La Timone Adultes, Marseille, CEDEX 5, France, <sup>9</sup>Centre Oscar Lambret, Lille, France, <sup>10</sup>Institut Gustave Roussy, Villejuif, France, <sup>11</sup>IHOPE - Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
- 13:15 - 13:30 **Invited Discussant abstracts 57MO, 58MO and 59MO**
- George Demetri, Dana Farber Cancer Institute, Boston, MA, United States of America
- 13:30 - 13:35 **60MO - Theranostics in soft tissue sarcoma using a vascular disruption approach: Preliminary results of a proof-of-concept pilot study**
- Antonia Digkila<sup>1</sup>; S. Boughdad<sup>1</sup>; A. Dolcan<sup>1</sup>; S. Peters<sup>1</sup>; G. Coukos<sup>2</sup>; J. Prior<sup>1</sup>; N. Schaefer<sup>1</sup>, <sup>1</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, <sup>2</sup>UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, Switzerland
- 13:35 - 13:40 **14MO - Safety of cytoreductive surgery with hyperthermic intraperitoneal gemcitabine and systemic dacarbazine for recurrent uterine leiomyosarcoma: Preliminary results of a phase II trial**
- Beatrice Sun<sup>1</sup>; N. Bui<sup>2</sup>; K. Ganjoo<sup>2</sup>; B. Lee<sup>1</sup>, <sup>1</sup>Stanford University School of Medicine, Stanford, United States of America, <sup>2</sup>Stanford Cancer Center Palo Alto, Palo Alto, United States of America
- 13:40 - 13:45 **61MO - Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)**
- Peter Reichardt<sup>1</sup>; P. Schöffski<sup>2</sup>; P. Lorusso<sup>3</sup>; N. Yamamoto<sup>4</sup>; V. Moreno Garcia<sup>5</sup>; I. Lugowska<sup>6</sup>; U. Lauer<sup>7</sup>; N. Somaiah<sup>8</sup>; C. Hu<sup>9</sup>; H. Landsteiner<sup>10</sup>; G. Jayadeva<sup>9</sup>; M. Gounder<sup>11</sup>, <sup>1</sup>Helios Klinikum Berlin-Buch, Berlin, Germany, <sup>2</sup>University Hospitals Leuven, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium, <sup>3</sup>Yale Cancer Center, New Haven, CT, United States of America, <sup>4</sup>National Cancer Center Hospital, Tokyo, Japan, <sup>5</sup>Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, <sup>6</sup>Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland, <sup>7</sup>University Hospital Tübingen, Tübingen, Germany, <sup>8</sup>Sarcoma Medical Oncology, Houston, TX, United States of America, <sup>9</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States of America, <sup>10</sup>Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria, <sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, NY, United States of America



13:45 - 14:00 **Invited Discussant abstracts 60MO, 14MO and 61MO**  
Marco Fiore, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

**13:00 - 14:00** **Type: Controversy session** **Hall B1**  
**Title: The mandatory centralisation of care in rare cancer reference centres: Does it always serve the patient benefit?**  
Moderation: Claudia María Valverde Morales, Spain

13:00 - 13:10 **Introduction and first vote**  
Claudia María Valverde Morales, Vall d'Hebron University Hospital, Barcelona, Spain

13:10 - 13:30 **Yes**  
Mikael Eriksson, Skane University Hospital, Lund, Sweden

13:30 - 13:50 **No**  
Alessandro Gronchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:50 - 14:00 **Second vote and conclusions/discussion**  
Claudia María Valverde Morales, Vall d'Hebron University Hospital, Barcelona, Spain

**14:15 - 15:45** **Type: Educational session** **Hall A**  
**Title: Retroperitoneal sarcoma**  
Moderation: Roberta Sanfilippo, Italy; Piotr Rutkowski, Poland

14:15 - 14:35 **Has R2 surgery a role?**  
Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

14:35 - 14:55 **IOR in retroperitoneal sarcomas**  
Rick L. Haas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

14:55 - 15:15 **When to consider perioperative chemotherapy?**  
Suzanne George, Dana Farber Cancer Institute, Boston, MA, United States of America

15:15 - 15:35 **What to do with rare histotypes?**  
Roberta Sanfilippo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

15:35 - 15:45 **Q&A and discussion**



<b>14:15 - 15:45</b>	<b>Type: Educational session</b> <b>Title: Gynaecological cancers</b> Moderation: Florence Joly Lobbedez, France; Michael Seckl, United Kingdom	<b>Hall B1</b>
14:15 - 14:35	<b>Late effects of treatment for non-epithelial cancer with a focus on cancer survivors</b> <u>Florence Joly Lobbedez</u> , Centre Francois Baclesse, Caen, Cedex 5, CEDEX 5, France	
14:35 - 14:55	<b>Which systemic therapies for vulvar cancer: Now and tomorrow</b> <u>Elsa Kalbacher</u> , Centre Jean PERRIN, Clermont-Ferrand, Cedex 01, CEDEX, France	
14:55 - 15:15	<b>Molecular profile of rare uterine cancer and impact on systemic therapies</b> <u>Alice Bergamini</u> , IRCCS Ospedale San Raffaele, Milan, Italy	
15:15 - 15:35	<b>GTD: What next?</b> <u>Michael Seckl</u> , Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, United Kingdom	
15:35 - 15:45	<b>Q&amp;A and discussion</b>	
<b>15:45 - 16:15</b>	<b>Type: Coffee break</b> <b>Title: Coffee break</b>	<b>Foyer Ground Floor</b>
<b>16:15 - 17:45</b>	<b>Type: Educational session</b> <b>Title: New molecular entities in sarcoma</b> Moderation: Judith Bovée, Netherlands; A. Paolo Dei Tos, Italy	<b>Hall A</b>
16:15 - 16:35	<b>Round cell sarcomas with EWSR1-non-ETS fusion</b> <u>Judith Bovée</u> , LUMC-Leiden University Medical Center, Leiden, Netherlands	
16:35 - 16:55	<b>NTRK-rearranged spindle cell neoplasm</b> <u>Daniel Lindsay</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
16:55 - 17:15	<b>Atypical spindle cell / pleomorphic lipomatous tumour and Myxoid pleomorphic liposarcoma</b> <u>A. Paolo Dei Tos</u> , University of Padua - School of Medicine, Padova, Italy	
17:15 - 17:35	<b>Poorly differentiated chordoma</b> <u>Silvia Bagué Rosell</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, Spain	
17:35 - 17:45	<b>Q&amp;A and discussion</b>	



<b>16:15 - 17:45</b>	<b>Type: Educational session</b> <b>Title: Uveal melanoma</b> Moderation: Sophie Piperno-Neumann, France; Ellen Kapiteijn, Netherlands	<b>Hall B1</b>
16:15 - 16:35	<b>Genetics and immunology</b> <u>Sarah Coupland</u> , NHS Liverpool Clinical Laboratories - Royal Liverpool University Hospital NHS Trust, Liverpool, United Kingdom	
16:35 - 16:55	<b>Patient preferences in the treatment of the primary tumour and screening for metastases</b> <u>Anne Brédart</u> , Institut Curie, Paris, France	
16:55 - 17:15	<b>Registries/real-life data</b> <u>Ellen Kapiteijn</u> , Leiden University Medical Center (LUMC), Leiden, Netherlands	
17:15 - 17:35	<b>New developments in systemic treatment</b> <u>Iwona Lugowska</u> , Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland	
17:35 - 17:45	<b>Q&amp;A and discussion</b>	
<b>16:15 - 17:45</b>	<b>Type: Special session</b> <b>Title: SPAGN session: The value of patient involvement and patient advocacy</b> Moderation: Markus Wartenberg, Germany	<b>Hall B3</b>
16:15 - 16:35	<b>The value of patient input in sarcoma research</b> <u>Markus Wartenberg</u> , Das Lebenshaus e.V., Wölfersheim, Hessen, Germany	
16:35 - 16:55	<b>The value of patient information and empowerment</b> <u>Natalia Fernandez Diaz</u> , UAB - Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain	
16:55 - 17:15	<b>The value of the patient voice from an expert view</b> <u>Bernd Kasper</u> , UMM - Universitätsklinikum Mannheim, Mannheim, Germany	
17:15 - 17:35	<b>The value of patient input in HTA</b> <u>Jayne Bressington</u> , GIST Cancer UK & PAWS-GIST, Chippenham, United Kingdom	
17:35 - 17:45	<b>Q&amp;A and discussion</b>	



16.03.2024

**08:30 - 10:00**    **Type: Educational session**    **Hall A**  
**Title: Desmoids**  
Moderation: Bernd Kasper, Germany; Justine Gantzer, France

08:30 - 08:50    **Does surgery still have any role?**  
Marco Fiore, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

08:50 - 09:10    **Hormonal treatment revisited in 2024**  
Robin Jones, The Royal Marsden Hospital - Chelsea, London, WA, United Kingdom

09:10 - 09:30    **The positioning of gamma secretase inhibitors in the management of desmoid tumours**  
Bernd Kasper, UMM - Universitaetsklinikum Mannheim, Mannheim, Germany

09:30 - 09:50    **Long-term outcome patients / cryotherapy?**  
Justine Gantzer, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, CEDEX, France

09:50 - 10:00    **Q&A and discussion**





**08:30 - 10:00**    **Type: Educational session**    **Hall B3**  
**Title: Rare thyroid and thymic cancers**  
Moderation: Alfredo Berruti, Italy; Rocio Garcia-Carbonero, Spain

08:30 - 08:45    **Anaplastic thyroid carcinoma**  
Laura Locati, University of Pavia, Pavia, Italy

08:45 - 09:00    **Medullary thyroid carcinoma**  
Jolanta Krajewska, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, Poland

09:00 - 09:15    **Parathyroid carcinoma**  
Désirée Deandreis, University of Turin, Torino, Italy

09:15 - 09:30    **Intrathyroid thymic carcinoma**  
Alfredo Berruti, ASST Spedali Civili di Brescia, Brescia, Italy

09:30 - 09:40    **260 - Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival**  
Alexander Sun-Zhang<sup>1</sup>; C. Juhlin<sup>1</sup>; T. Carling<sup>2</sup>; U. Scholl<sup>3</sup>; C. Larsson<sup>1</sup>; S. Bajalica Lagercrantz<sup>1</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, Sweden, <sup>2</sup>Carling Adrenal Center, Tampa, Florida, United States of America, <sup>3</sup>Charité - Universitätsmedizin Berlin, Berlin, Germany

09:40 - 09:45    **Invited Discussant abstract 260**  
Rodrigo Toledo, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain

09:45 - 10:00    **Q&A and discussion**

**10:00 - 10:30**    **Type: Coffee break**    **Foyer Ground Floor**  
**Title: Coffee break**



**10:30 - 12:00**    **Type: Educational session**    **Hall A**  
**Title: The role of networks in advancing patient care in sarcomas**  
Moderation: Jean-Yves Blay, France; Ashleigh Guadagnolo, United States of America

10:30 - 10:50    **EuroEwing**  
Sandra Strauss, University College London Hospitals NHS Foundation Trust, London, United Kingdom

10:50 - 11:10    **SELNET**  
Alberto Righi, IOR - Istituto Ortopedico Rizzoli - IRCCS, Bologna, Italy

11:10 - 11:30    **FOSTER**  
Nathalie Gaspar, Institut Gustave Roussy, Villejuif, Cedex, France

11:30 - 11:50    **EURACAN**  
Jean-Yves Blay, Centre Léon Bérard, Lyon, CEDEX, France

11:50 - 12:00    **Q&A and discussion**

**10:30 - 12:00**    **Type: Educational session**    **Hall B1**  
**Title: AI & deep learning**  
Moderation: Ioanna Nixon, United Kingdom; Jean Michel Coindre, France

10:30 - 10:50    **Deep learning in histology of rare tumours: example of GIST**  
Jean Michel Coindre, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, CEDEX, France

10:50 - 11:10    **Deciphering tumour heterogeneity: Empowering insights through self-supervised AI**  
Aristotelis Tsirigos, New York University, New York, United States of America

11:10 - 11:30    **Exploiting electronic health records through AI**  
Ioanna Nixon, The Beatson West of Scotland Cancer Center, Glasgow, United Kingdom

11:30 - 11:50    **Radiomics and the future of radiology in rare tumours**  
Sandro Pasquali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy

11:50 - 12:00    **Q&A and discussion**



<b>10:30 - 12:00</b>	<b>Type: Educational session</b> <b>Title: Head &amp; neck cancers: Private biology or in common with other cancers?</b>	<b>Hall B3</b>
	Moderation: Christopher French, United States of America; Lisa Licitra, Italy	
10:30 - 10:45	<b>Neuroendocrine histotypes of head and neck cancers</b> <u>Lisa Licitra</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
10:45 - 11:00	<b>SmarcB1 (INI-1)- deficient cancers</b> <u>Abbas Agaimy</u> , Universitaetsklinikum Erlangen - Pathologisches Institut, Erlangen, Germany	
11:00 - 11:15	<b>NUTs of the head and neck region</b> <u>Christopher French</u> , Brigham and Women's Hospital, Boston, United States of America	
11:15 - 11:30	<b>Non-endemic nasopharyngeal cancers</b> <u>Loris De Cecco</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy	
11:30 - 11:40	<b>1470 - Scope of NUT carcinomas (NC): An international multicentric study</b> <u>Maria Virginia Sanchez Becerra</u> <sup>1</sup> ; M. Knetki-Wroblewska <sup>2</sup> ; S. O'Reilly <sup>3</sup> ; M. Bover Larroya <sup>4</sup> ; J.C. Benitez Montañez <sup>5</sup> ; P. Martin Martorell <sup>6</sup> ; S. Sandiego Contreras <sup>7</sup> ; M.R. Ghigna <sup>8</sup> ; C. Markellos <sup>9</sup> ; M. Burgy <sup>10</sup> ; P. Hulo <sup>11</sup> ; Q. Mangon <sup>12</sup> ; R. Motta Guerrero <sup>13</sup> ; J. Chapron <sup>14</sup> ; P. Lavaud <sup>15</sup> ; C. Massard <sup>8</sup> ; C. Even <sup>16</sup> ; N. Cozic <sup>8</sup> ; B. Fresneau <sup>16</sup> ; B. Besse <sup>17</sup> , <sup>1</sup> Gustave Roussy, Villejuif, France, <sup>2</sup> Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>3</sup> The Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>4</sup> Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>5</sup> Hospital Universitario Virgen de la Victoria, MALAGA, Spain, <sup>6</sup> Hospital Clinico Universitario de Valencia, Valencia, Valencia, Spain, <sup>7</sup> IVO - Fundación Instituto Valenciano de Oncología, Valencia, Spain, <sup>8</sup> Gustave Roussy - Cancer Campus, Villejuif, France, <sup>9</sup> Alexandra Hospital - National & Kapodistrian University of Athens, Athens, Greece, <sup>10</sup> ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, CEDEX, France, <sup>11</sup> CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, France, <sup>12</sup> CHU Gabriel-Montpied, Clermont-Ferrand, Cedex, CEDEX 1, France, <sup>13</sup> Aliada - Contra el cancer - Centro Oncologico, Lima, Peru, <sup>14</sup> Assistance Publique - Hopitaux De Paris, Paris, France, <sup>15</sup> Institut Gustave Roussy, Villejuif, Cedex, CEDEX 14, France, <sup>16</sup> Institut Gustave Roussy, Villejuif, Cedex, France, <sup>17</sup> Institut Gustave Roussy, Villejuif, Cedex, CEDEX, France	
11:40 - 11:45	<b>Invited Discussant abstract 1470</b> <u>Javier Martinez Trufero</u> , HospItal Universitario Miguel Servet, Zaragoza, Spain	
11:45 - 12:00	<b>Q&amp;A and discussion</b>	
<b>12:00 - 13:00</b>	<b>Type: Lunch break</b> <b>Title: Lunch</b>	<b>Foyer Ground Floor</b>



**13:00 - 14:30**    **Type: Educational session**    **Hall A**  
**Title: RWD: How to generate and apply it in sarcoma?**  
Moderation: Paul Huang, United Kingdom; Iwona Lugowska, Poland

13:00 - 13:20    **Practical challenges in data, imaging and tissue transfer in multi-lateral collaborations**  
Paul Huang, ICR - Institute of Cancer Research, London, United Kingdom

13:20 - 13:35    **Methodological issues and usefulness**  
Herbert Ho Fung Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong PRC

13:35 - 13:50    **Real-world data in soft tissue sarcomas**  
Anastasia Constantinidou, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

13:50 - 14:05    **Real-world evidence and osteosarcoma**  
Stefan Bielack, Klinikum Stuttgart - Olgahospital / Frauenklinik, Stuttgart, Germany

14:05 - 14:30    **Conclusion, Q&A and discussion**  
Iwona Lugowska<sup>1</sup>; Paul Huang<sup>2</sup>, <sup>1</sup>Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland, <sup>2</sup>ICR - Institute of Cancer Research, London, United Kingdom

**13:00 - 14:30**    **Type: Educational session**    **Hall B1**  
**Title: Accreditation as a means for quality improvement**  
Moderation: Claudia María Valverde Morales, Spain; Ioanna Nixon, United Kingdom

13:00 - 13:25    **Defining criteria: A hard work in progress CRANE**  
Sigbjørn Smeland, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway

13:25 - 13:50    **Europe looks into the future: CCI4EU**  
Josep Borrás, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain

13:50 - 14:15    **The patient perspective**  
Natalia Fernández Díaz, CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, Spain

14:15 - 14:30    **Q&A and discussion**



<b>13:00 - 14:30</b>	<b>Type: Educational session</b> <b>Title: Neuroendocrine tumours</b> Moderation: Rocio Garcia-Carbonero, Spain; Justo Castaño, Spain	<b>Hall B3</b>
13:00 - 13:15	<b>Lung and Digestive NETs: Convergent biology and site-specific molecular features</b> <u>Justo Castaño</u> , IMIBIC - Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain	
13:15 - 13:30	<b>Pathological diagnosis: Tips and traps</b> <u>Aurel Perren</u> , University of Bern - Institute of Pathology, Bern, Switzerland	
13:30 - 13:45	<b>Hormonal crisis prevention and management</b> <u>Antongiulio Faggiano</u> , Sapienza Università di Roma, Rome, Italy	
13:45 - 14:00	<b>Systemic therapy for advanced NENs: What's new in the field?</b> <u>Rocio Garcia-Carbonero</u> , University Hospital 12 De Octubre, Madrid, Spain	
14:00 - 14:10	<b>270 - Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)</b> <u>Rocio Garcia-Carbonero</u> <sup>1</sup> ; G. Cote <sup>2</sup> ; A. Le Cesne <sup>3</sup> ; B. Anton-Pascual <sup>1</sup> ; T. Alonso Gordo <sup>4</sup> ; A. Falcon Gonzalez <sup>5</sup> ; A. Gil Torralvo <sup>5</sup> ; S. Martinez <sup>6</sup> ; M. Sigüero <sup>6</sup> ; M. Cullell <sup>6</sup> ; S. Fudio <sup>6</sup> ; A. Zeaiter <sup>6</sup> ; J. Molina Cerrillo <sup>4</sup> , <sup>1</sup> Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain, <sup>2</sup> Mass General Cancer Center, Boston, MA, United States of America, <sup>3</sup> Institut Gustave Roussy, Villejuif, CEDEX, France, <sup>4</sup> Hospital Universitario Ramon y Cajal, Madrid, Spain, <sup>5</sup> Hospital Universitario Virgen del Rocío, Seville, Spain, <sup>6</sup> PharmaMar S.A., Colmenar Viejo, Spain	
14:10 - 14:15	<b>Invited Discussant abstract 270</b> <u>Lucjan Wyrwicz</u> , Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland	
14:15 - 14:30	<b>Q&amp;A and discussion</b>	